JP2005512990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512990A5 JP2005512990A5 JP2003541764A JP2003541764A JP2005512990A5 JP 2005512990 A5 JP2005512990 A5 JP 2005512990A5 JP 2003541764 A JP2003541764 A JP 2003541764A JP 2003541764 A JP2003541764 A JP 2003541764A JP 2005512990 A5 JP2005512990 A5 JP 2005512990A5
- Authority
- JP
- Japan
- Prior art keywords
- valdecoxib
- composition
- present
- compositions
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 164
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 84
- 229960002004 valdecoxib Drugs 0.000 description 82
- -1 4- (5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide compound Chemical class 0.000 description 42
- 239000003814 drug Substances 0.000 description 36
- 229940079593 drugs Drugs 0.000 description 35
- 238000004090 dissolution Methods 0.000 description 33
- 201000010099 disease Diseases 0.000 description 20
- 235000003599 food sweetener Nutrition 0.000 description 20
- 239000003765 sweetening agent Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 150000001720 carbohydrates Chemical class 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 16
- 239000008187 granular material Substances 0.000 description 16
- 239000000546 pharmaceutic aid Substances 0.000 description 16
- 210000000214 Mouth Anatomy 0.000 description 15
- 239000000314 lubricant Substances 0.000 description 14
- 230000001953 sensory Effects 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 239000007884 disintegrant Substances 0.000 description 11
- 239000007921 spray Substances 0.000 description 11
- 230000001225 therapeutic Effects 0.000 description 11
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 10
- 102100015381 PTGS2 Human genes 0.000 description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000080 wetting agent Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- WBZFUFAFFUEMEI-UHFFFAOYSA-N Acesulfame potassium Chemical compound [K+].CC1=CC(=O)NS(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-N 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000000619 acesulfame-K Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 230000001976 improved Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 5
- 206010019233 Headache Diseases 0.000 description 5
- 230000037165 Serum Concentration Effects 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 230000000202 analgesic Effects 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 206010001897 Alzheimer's disease Diseases 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 206010022114 Injury Diseases 0.000 description 4
- 240000006217 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Polymers 0.000 description 4
- 230000003364 opioid Effects 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 235000006678 peppermint Nutrition 0.000 description 4
- 235000015132 peppermint Nutrition 0.000 description 4
- 235000007735 peppermint Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940035676 ANALGESICS Drugs 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- 208000006673 Asthma Diseases 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 3
- 229960003406 Levorphanol Drugs 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010027599 Migraine Diseases 0.000 description 3
- 208000008085 Migraine Disorders Diseases 0.000 description 3
- 102100006335 PTGS1 Human genes 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increased Effects 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000002772 monosaccharides Chemical group 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N 1,4-dimethyl-7-(1-methylethyl)azulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 206010006811 Bursitis Diseases 0.000 description 2
- 230000035839 C max Effects 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000565118 Cordylophora caspia Species 0.000 description 2
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000009883 Joint Disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 244000024873 Mentha crispa Species 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 229940041655 Meperidine Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 210000003254 Palate Anatomy 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 206010061529 Polyp Diseases 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 240000002799 Prunus avium Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 210000003296 Saliva Anatomy 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 208000004371 Toothache Diseases 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229940053550 agents used for ADHD and nootropics psychostimulants Xanthine derivatives Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001754 anti-pyretic Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000000740 bleeding Effects 0.000 description 2
- 231100000319 bleeding Toxicity 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000002919 epithelial cells Anatomy 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009477 fluid bed granulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 201000009673 liver disease Diseases 0.000 description 2
- 229940083747 low-ceiling diuretics Xanthine derivatives Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003533 narcotic Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 150000003814 prostanoids Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000003422 vasoregulatory Effects 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- DUEBHXGFCXXGHK-CVEARBPZSA-N (1S,2R)-2-amino-1,2-bis(4-methoxyphenyl)ethanol Chemical compound C1=CC(OC)=CC=C1[C@@H](N)[C@@H](O)C1=CC=C(OC)C=C1 DUEBHXGFCXXGHK-CVEARBPZSA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N (3-oxo-1H-2-benzofuran-1-yl) 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- LCCDINSFSOALJK-UHFFFAOYSA-N 1,3,4-trimethylpurine-2,6-dione Chemical class O=C1N(C)C(=O)N(C)C2(C)N=CN=C21 LCCDINSFSOALJK-UHFFFAOYSA-N 0.000 description 1
- ZZMSHBOVYPIYOB-UHFFFAOYSA-N 1,4-diphenylpyrazolidine-3,5-dione Chemical compound O=C1NN(C=2C=CC=CC=2)C(=O)C1C1=CC=CC=C1 ZZMSHBOVYPIYOB-UHFFFAOYSA-N 0.000 description 1
- XOZLRRYPUKAKMU-UHFFFAOYSA-N 1,5-dimethyl-2-phenyl-4-(propan-2-ylamino)pyrazol-3-one Chemical compound O=C1C(NC(C)C)=C(C)N(C)N1C1=CC=CC=C1 XOZLRRYPUKAKMU-UHFFFAOYSA-N 0.000 description 1
- WQAQKERCWPUIMH-UHFFFAOYSA-N 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CN1C(C)=CC(=O)N1C1=CC=CC=C1 WQAQKERCWPUIMH-UHFFFAOYSA-N 0.000 description 1
- XKFIQZCHJUUSBA-UHFFFAOYSA-N 1-(5-phenyl-1,2-oxazol-3-yl)-2-piperidin-1-ylethanol Chemical compound C1=C(C=2C=CC=CC=2)ON=C1C(O)CN1CCCCC1 XKFIQZCHJUUSBA-UHFFFAOYSA-N 0.000 description 1
- PRNNIHPVNFPWAH-UHFFFAOYSA-N 1-ethylsulfonyl-4-fluorobenzene Chemical compound CCS(=O)(=O)C1=CC=C(F)C=C1 PRNNIHPVNFPWAH-UHFFFAOYSA-N 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N 2-(11-oxo-6H-benzo[c][1]benzoxepin-2-yl)acetic acid Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- LZRDDINFIHUVCX-UHFFFAOYSA-N 2-(2,4,5-triphenylpyrazol-3-yl)acetic acid Chemical compound OC(=O)CC1=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LZRDDINFIHUVCX-UHFFFAOYSA-N 0.000 description 1
- RLISWLLILOTWGG-UHFFFAOYSA-N 2-(2-carbamoylphenoxy)acetic acid Chemical compound NC(=O)C1=CC=CC=C1OCC(O)=O RLISWLLILOTWGG-UHFFFAOYSA-N 0.000 description 1
- MUXFZBHBYYYLTH-UHFFFAOYSA-N 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 1
- AJRNYCDWNITGHF-UHFFFAOYSA-N 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-hydroxyacetamide Chemical compound CC1=C(CC(=O)NO)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AJRNYCDWNITGHF-UHFFFAOYSA-N 0.000 description 1
- DGMZLCLHHVYDIS-UHFFFAOYSA-N 2-[3-(4-chlorobenzoyl)-6-methoxy-2-methylindol-1-yl]acetic acid Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- UULSXYSSHHRCQK-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]butanoic acid Chemical compound CCC(C(O)=O)C1=CC=C(CC(C)C)C=C1 UULSXYSSHHRCQK-UHFFFAOYSA-N 0.000 description 1
- NKPPORKKCMYYTO-DHZHZOJOSA-N 2-[5-methoxy-2-methyl-1-[(E)-3-phenylprop-2-enoyl]indol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)\C=C\C1=CC=CC=C1 NKPPORKKCMYYTO-DHZHZOJOSA-N 0.000 description 1
- LSAMUAYPDHUBQD-RMKNXTFCSA-N 2-[[(E)-but-2-enoyl]-ethylamino]-N,N-dimethylbutanamide Chemical compound CN(C)C(=O)C(CC)N(CC)C(=O)\C=C\C LSAMUAYPDHUBQD-RMKNXTFCSA-N 0.000 description 1
- LJUNTZNMAYBZTA-UHFFFAOYSA-N 2-[bromo(hydroxy)methyl]phenol Chemical compound OC(Br)C1=CC=CC=C1O LJUNTZNMAYBZTA-UHFFFAOYSA-N 0.000 description 1
- JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N 2-hydroxy-5-(2-phenyl-4,5-dihydrobenzo[e]indol-3-yl)benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N 3,4,5,6-tetrahydro-5-methyl-1-phenyl-1H-2,5-Benzoxazocine Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- UCCJWNPWWPJKGL-UHFFFAOYSA-N 3-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxy-2-phenylpropanoic acid Chemical compound CC1=C(CC(=O)OCC(C(O)=O)C=2C=CC=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 UCCJWNPWWPJKGL-UHFFFAOYSA-N 0.000 description 1
- BUZICZZQJDLXJN-UHFFFAOYSA-N 3-azaniumyl-4-hydroxybutanoate Chemical compound OCC(N)CC(O)=O BUZICZZQJDLXJN-UHFFFAOYSA-N 0.000 description 1
- GAWOVNGQYQVFLI-UHFFFAOYSA-N 4-[(4-ethoxyphenyl)diazenyl]benzene-1,3-diamine Chemical compound C1=CC(OCC)=CC=C1N=NC1=CC=C(N)C=C1N GAWOVNGQYQVFLI-UHFFFAOYSA-N 0.000 description 1
- KMGARVOVYXNAOF-UHFFFAOYSA-N 4-benzyl-2-(1-methylpiperidin-4-yl)-5-phenyl-1H-pyrazol-3-one Chemical compound C1CN(C)CCC1N1C(=O)C(CC=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 KMGARVOVYXNAOF-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- DVEQCIBLXRSYPH-UHFFFAOYSA-N 5-butyl-1-cyclohexylbarbituric acid Chemical compound O=C1C(CCCC)C(=O)NC(=O)N1C1CCCCC1 DVEQCIBLXRSYPH-UHFFFAOYSA-N 0.000 description 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N 5-chloro-3-[2-[4-(2-hydroxyethyl)piperazin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one;hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-ol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 description 1
- WDSCBUNMANHPFH-UHFFFAOYSA-N 6-acetamidohexanoic acid Chemical compound CC(=O)NCCCCCC(O)=O WDSCBUNMANHPFH-UHFFFAOYSA-N 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N AZAPROPAZONE Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960004892 Acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N Acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N Acetanilide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N Alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960001391 Alfentanil Drugs 0.000 description 1
- 229940024642 Aminopyrine Drugs 0.000 description 1
- ISRODTBNJUAWEJ-UHFFFAOYSA-N Amixetrine Chemical compound C=1C=CC=CC=1C(OCCC(C)C)CN1CCCC1 ISRODTBNJUAWEJ-UHFFFAOYSA-N 0.000 description 1
- 229940063284 Ammonium salicylate Drugs 0.000 description 1
- LSNWBKACGXCGAJ-UHFFFAOYSA-N Ampiroxicam Chemical compound CN1S(=O)(=O)C2=CC=CC=C2C(OC(C)OC(=O)OCC)=C1C(=O)NC1=CC=CC=N1 LSNWBKACGXCGAJ-UHFFFAOYSA-N 0.000 description 1
- 229950011249 Ampiroxicam Drugs 0.000 description 1
- 206010063023 Analgesic asthma syndrome Diseases 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 229940091110 Antipyrine Drugs 0.000 description 1
- 229940091143 Apazone Drugs 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003284 Arthropathy Diseases 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000011497 Barrett's esophagus Diseases 0.000 description 1
- 206010004137 Barrett's oesophagus Diseases 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N Bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N Benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N Benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 208000006752 Brain Edema Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N Bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- FLWFHHFTIRLFPV-UHFFFAOYSA-N Bumadizone Chemical compound C=1C=CC=CC=1N(C(=O)C(C(O)=O)CCCC)NC1=CC=CC=C1 FLWFHHFTIRLFPV-UHFFFAOYSA-N 0.000 description 1
- 229960002973 Butibufen Drugs 0.000 description 1
- QDUYCDLQSUFWSX-UHFFFAOYSA-N C(C)(=O)OC=1C(C(=O)O)=CC=CC1.C(C)(=O)OC=1C(C(=O)O)=CC=CC1.[Al] Chemical compound C(C)(=O)OC=1C(C(=O)O)=CC=CC1.C(C)(=O)OC=1C(C(=O)O)=CC=CC1.[Al] QDUYCDLQSUFWSX-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- GEPVMDINFCTKRV-UHFFFAOYSA-N CC1(N=C2NC(NC(C2=N1)=O)=O)C Chemical class CC1(N=C2NC(NC(C2=N1)=O)=O)C GEPVMDINFCTKRV-UHFFFAOYSA-N 0.000 description 1
- 229960001209 CLONIXIN Drugs 0.000 description 1
- LGAJOMLFGCSBFF-XVBLYABRSA-N COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O Chemical compound COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O LGAJOMLFGCSBFF-XVBLYABRSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 208000001969 Capillary Hemangioma Diseases 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 208000000350 Central Nervous System Disease Diseases 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 210000003467 Cheek Anatomy 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000002268 Citrus limon Species 0.000 description 1
- 229950010886 Clidanac Drugs 0.000 description 1
- 229950001647 Clometacin Drugs 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N Clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 206010009802 Coagulopathy Diseases 0.000 description 1
- 206010053567 Coagulopathy Diseases 0.000 description 1
- 229960004415 Codeine Phosphate Drugs 0.000 description 1
- 229960003871 Codeine sulfate Drugs 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000008313 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N DL-leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N Desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- HGKAMARNFGKMLC-RBUKOAKNSA-N Dexoxadrol Chemical compound C([C@H]1[C@@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-RBUKOAKNSA-N 0.000 description 1
- 229950004665 Dexoxadrol Drugs 0.000 description 1
- 229960003701 Dextromoramide Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N Dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 229960001193 Diclofenac Sodium Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N Dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Dimethyl N aminoantipyrine Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- CANBGVXYBPOLRR-UHFFFAOYSA-N Dimethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)C)C1=CC=CS1 CANBGVXYBPOLRR-UHFFFAOYSA-N 0.000 description 1
- 229950005563 Dimethylthiambutene Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M Dioctyl sodium sulfosuccinate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940120889 Dipyrone Drugs 0.000 description 1
- UUCMDZWCRNZCOY-UHFFFAOYSA-N Ditazole Chemical compound O1C(N(CCO)CCO)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UUCMDZWCRNZCOY-UHFFFAOYSA-N 0.000 description 1
- 208000007784 Diverticulitis Diseases 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N Droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010052828 Eosinophilic disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- 229960004578 Ethylmorphine Drugs 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N Etofenamate Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- PXDBZSCGSQSKST-UHFFFAOYSA-N Etonitazene Chemical compound C1=CC(OCC)=CC=C1CC1=NC2=CC([N+]([O-])=O)=CC=C2N1CCN(CC)CC PXDBZSCGSQSKST-UHFFFAOYSA-N 0.000 description 1
- 229950004538 Etonitazene Drugs 0.000 description 1
- 229950008765 Etoxazene Drugs 0.000 description 1
- 229960002217 Eugenol Drugs 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229950004250 FLUPROQUAZONE Drugs 0.000 description 1
- OPTZOXDYEFIPJZ-UHFFFAOYSA-N Falimint Chemical compound CCCOC1=CC=C([N+]([O-])=O)C=C1NC(C)=O OPTZOXDYEFIPJZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229950005416 Fendosal Drugs 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- 229960004369 Flufenamic Acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N Flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 229950011300 Fluoresone Drugs 0.000 description 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N Flupirtine Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 1
- ZWOUXWWGKJBAHQ-UHFFFAOYSA-N Fluproquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=C(F)C=C1 ZWOUXWWGKJBAHQ-UHFFFAOYSA-N 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 240000001441 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 208000008032 Gastrointestinal Hemorrhage Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 210000004195 Gingiva Anatomy 0.000 description 1
- 208000007565 Gingivitis Diseases 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 229940015001 Glycerin Drugs 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 206010061992 Haemophilia Diseases 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- BYPIURIATSUHDW-UHFFFAOYSA-N Ibuproxam Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NO)C=C1 BYPIURIATSUHDW-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N Indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhage Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N Isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
- 229950000248 Isonixin Drugs 0.000 description 1
- 229950011455 Isoxepac Drugs 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 229940039371 Karaya Gum Drugs 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- YEJZJVJJPVZXGX-MRXNPFEDSA-N Lefetamine Chemical compound C([C@@H](N(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 YEJZJVJJPVZXGX-MRXNPFEDSA-N 0.000 description 1
- 208000009059 Leukoencephalopathy Diseases 0.000 description 1
- INUNXTSAACVKJS-NRFANRHFSA-N Levomoramide Chemical compound C([C@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-NRFANRHFSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N Lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- YEOTYALSMRNXLJ-UHFFFAOYSA-N Metazosin Chemical compound C1CN(C(=O)C(C)OC)CCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 YEOTYALSMRNXLJ-UHFFFAOYSA-N 0.000 description 1
- 229960005189 Methadone Hydrochloride Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N Mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- DJEIHHYCDCTAAH-UHFFFAOYSA-N Mofezolac Chemical compound C1=CC(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1 DJEIHHYCDCTAAH-UHFFFAOYSA-N 0.000 description 1
- 229960004715 Morphine Sulfate Drugs 0.000 description 1
- 206010028323 Muscle pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- GODGZZGKTZQSAL-VXFFQEMOSA-N Myrophine Chemical compound C([C@@H]1[C@@H]2C=C[C@@H]([C@@H]3OC4=C5[C@]23CCN1C)OC(=O)CCCCCCCCCCCCC)C5=CC=C4OCC1=CC=CC=C1 GODGZZGKTZQSAL-VXFFQEMOSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- WJDDCFNFNAHLAF-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-oxo-1H-pyridine-3-carboxamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC=CNC1=O WJDDCFNFNAHLAF-UHFFFAOYSA-N 0.000 description 1
- MSLICLMCQYQNPK-UHFFFAOYSA-N N-(4-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C=C1 MSLICLMCQYQNPK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- QTNZYVAMNRDUAD-UHFFFAOYSA-N N-[4-[(2-methylpropan-2-yl)oxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(OC(C)(C)C)C=C1 QTNZYVAMNRDUAD-UHFFFAOYSA-N 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N N-acetyl-2-hydroxybenzamide Chemical compound CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 229940073555 NONOXYNOL-10 Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N Nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 Nalbuphine Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 229960000751 Nefopam Drugs 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N Neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108009000551 Nephrotic syndrome Proteins 0.000 description 1
- 208000004296 Neuralgia Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N Nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- BRZANEXCSZCZCI-UHFFFAOYSA-N Nifenazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C)C(C)=C1NC(=O)C1=CC=CN=C1 BRZANEXCSZCZCI-UHFFFAOYSA-N 0.000 description 1
- 229960000916 Niflumic Acid Drugs 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N Nonoxynol-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 229940087419 Nonoxynol-9 Drugs 0.000 description 1
- 229950011519 Norlevorphanol Drugs 0.000 description 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N Normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 description 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 description 1
- 229950006134 Normorphine Drugs 0.000 description 1
- WCDSHELZWCOTMI-UHFFFAOYSA-N Norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 description 1
- 229940098514 Octoxynol-9 Drugs 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N Olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 229950006445 PIMINODINE Drugs 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- CPJSUEIXXCENMM-UHFFFAOYSA-N Phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
- 229960003893 Phenacetin Drugs 0.000 description 1
- LOXCOAXRHYDLOW-UHFFFAOYSA-N Phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 description 1
- 229950004540 Phenadoxone Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N Phenazone Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 229960003799 Phenazopyridine hydrochloride Drugs 0.000 description 1
- 229960004315 Phenoperidine Drugs 0.000 description 1
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N Phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- PXXKIYPSXYFATG-UHFFFAOYSA-N Piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000000399 Procedural Pain Diseases 0.000 description 1
- 229960003192 Propacetamol Drugs 0.000 description 1
- QTGAJCQTLIRCFL-UHFFFAOYSA-N Propacetamol Chemical compound CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1 QTGAJCQTLIRCFL-UHFFFAOYSA-N 0.000 description 1
- 229940069956 Propoxyphene Drugs 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N Propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N Proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 229960003394 Remifentanil Drugs 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038932 Retinopathy Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010072736 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940081973 S-Adenosylmethionine Drugs 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine zwitterion Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 229940085605 Saccharin Sodium Drugs 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N Salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229960001462 Sodium Cyclamate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L Sodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229960004739 Sufentanil Drugs 0.000 description 1
- 229960001940 Sulfasalazine Drugs 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide Dismutase Proteins 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000005147 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 230000037098 T max Effects 0.000 description 1
- 102100002996 TAC1 Human genes 0.000 description 1
- 101700065588 TAC1 Proteins 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 229960004412 Thebacon Drugs 0.000 description 1
- RRJQTGHQFYTZOW-ILWKUFEGSA-N Thebacon Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C=C(OC(C)=O)[C@@H]1OC1=C2C3=CC=C1OC RRJQTGHQFYTZOW-ILWKUFEGSA-N 0.000 description 1
- 229960004559 Theobromine Drugs 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N Tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229960004380 Tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229940117013 Triethanolamine oleate Drugs 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229950004227 Zaltoprofen Drugs 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- UVITTYOJFDLOGI-LICQEQMYSA-N [(2S,5R)-1,2,5-trimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)C[C@H](C)N(C)C[C@H]1C UVITTYOJFDLOGI-LICQEQMYSA-N 0.000 description 1
- IYFATESGLOUGBX-NDUCAMMLSA-N [2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-NDUCAMMLSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004582 acexamic acid Drugs 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- WEUCPZFPBXPCQU-UHFFFAOYSA-K aluminum;2-acetyloxybenzoate;dihydroxide Chemical compound O[Al+]O.CC(=O)OC1=CC=CC=C1C([O-])=O WEUCPZFPBXPCQU-UHFFFAOYSA-K 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- 229950001993 amixetrine Drugs 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 229940121363 anti-inflammatory agents Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 201000008804 arthropathy Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- BOFZOTMTKBQRAB-UHFFFAOYSA-N azanium;2-carboxyphenolate Chemical compound N.OC(=O)C1=CC=CC=C1O BOFZOTMTKBQRAB-UHFFFAOYSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 201000000488 breast squamous cell carcinoma Diseases 0.000 description 1
- 229950003872 bucolome Drugs 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- 229960003354 bumadizone Drugs 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 229950011189 butacetin Drugs 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- KRALOLGXHLZTCW-UHFFFAOYSA-L calcium;2-acetyloxybenzoate Chemical compound [Ca+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O KRALOLGXHLZTCW-UHFFFAOYSA-L 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 230000002149 cannabinoid Effects 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000008779 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002113 chemopreventative Effects 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 229950011171 cinmetacin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 201000009230 common cold Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 229950008678 crotetamide Drugs 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 229950003851 desomorphine Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960005067 ditazole Drugs 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IPOPQVVNCFQFRK-UHFFFAOYSA-N ethyl 1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 201000010868 female reproductive system disease Diseases 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 229960001321 flunoxaprofen Drugs 0.000 description 1
- ARPYQKTVRGFPIS-VIFPVBQESA-N flunoxaprofen Chemical compound N=1C2=CC([C@@H](C(O)=O)C)=CC=C2OC=1C1=CC=C(F)C=C1 ARPYQKTVRGFPIS-VIFPVBQESA-N 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229960004410 glucametacin Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 201000005569 gout Diseases 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 229940057502 guaiazulene Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002595 ibuproxam Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 229950004425 isofezolac Drugs 0.000 description 1
- 229950009272 isomethadone Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229950008279 lefetamine Drugs 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- RBLKLJDYAHZCFW-UHFFFAOYSA-L magnesium;2-acetyloxybenzoate Chemical compound [Mg+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O RBLKLJDYAHZCFW-UHFFFAOYSA-L 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229940072739 mesalamine Drugs 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229950000257 metamizole Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- 229960000429 mofezolac Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229930014694 morphine Natural products 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 201000002481 myositis Diseases 0.000 description 1
- 229950007471 myrophine Drugs 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- CVRCFLFEGNKMEC-UHFFFAOYSA-N naphthalen-1-yl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC2=CC=CC=C12 CVRCFLFEGNKMEC-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 201000009384 neuromuscular junction disease Diseases 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- 229960002187 nifenazone Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 229960004013 normethadone Drugs 0.000 description 1
- 229950007418 norpipanone Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229960000273 oxametacin Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- GHZNWXGYWUBLLI-UHFFFAOYSA-N p-Lactophenetide Chemical compound CCOC1=CC=C(NC(=O)C(C)O)C=C1 GHZNWXGYWUBLLI-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229960003294 papaveretum Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229950005491 perisoxal Drugs 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- QQBPIHBUCMDKFG-UHFFFAOYSA-N phenazopyridine hydrochloride Chemical compound Cl.NC1=NC(N)=CC=C1N=NC1=CC=CC=C1 QQBPIHBUCMDKFG-UHFFFAOYSA-N 0.000 description 1
- PSBAIJVSCTZDDB-UHFFFAOYSA-N phenyl 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 PSBAIJVSCTZDDB-UHFFFAOYSA-N 0.000 description 1
- 229950009058 phenyl acetylsalicylate Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- 201000007183 prothrombin deficiency Diseases 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229950000385 ramifenazone Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229950009280 salacetamide Drugs 0.000 description 1
- 229950000417 salamidacetic acid Drugs 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960005262 talniflumate Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229950002470 tropesin Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 102000037289 κ-opioid receptors Human genes 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
- 102000037275 Ό-opioid receptors Human genes 0.000 description 1
- 108020001612 Ό-opioid receptors Proteins 0.000 description 1
Description
çºæã®å±ããæè¡åé
æ¬çºæã¯ããã«ãã³ãã·ãã掻æ§æåãšããŠå«ãå£è å 厩å£åå»è¬çµæç©ããããçµæç©ã®è£œé æ¹æ³ãããã³ãããçµæç©ã被éšè ã«çµå£æäžããããšãå«ãã§ãªãã·ã¯ããªãã·ã²ããŒãŒïŒåªä»æ§çŸæ£ã®æ²»çæ³ã«é¢ããã
çºæã®èæ¯
4-(5-ã¡ãã«-3-ãã§ãã«-4-ã€ãœãªããµãŸãªã«)ãã³ãŒã³ã¹ã«ãã³ã¢ãããšããååç©(
æ¬æ现æžã§ã¯ãã«ãã³ãã·ããšãåŒã¶)ã¯ãæ¬ååç©ããã³é¢é£ååç©ã®è£œé æ¹æ³ãšå ±ã«
ãTalley ããžã®ç±³åœç¹èš±ç¬¬5,633,272å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«é瀺ãããããã«ãã³ãã·ãã¯ä»¥äžã®æ§é ãæããã
æ¬çºæã¯ããã«ãã³ãã·ãã掻æ§æåãšããŠå«ãå£è å 厩å£åå»è¬çµæç©ããããçµæç©ã®è£œé æ¹æ³ãããã³ãããçµæç©ã被éšè ã«çµå£æäžããããšãå«ãã§ãªãã·ã¯ããªãã·ã²ããŒãŒïŒåªä»æ§çŸæ£ã®æ²»çæ³ã«é¢ããã
çºæã®èæ¯
4-(5-ã¡ãã«-3-ãã§ãã«-4-ã€ãœãªããµãŸãªã«)ãã³ãŒã³ã¹ã«ãã³ã¢ãããšããååç©(
æ¬æ现æžã§ã¯ãã«ãã³ãã·ããšãåŒã¶)ã¯ãæ¬ååç©ããã³é¢é£ååç©ã®è£œé æ¹æ³ãšå ±ã«
ãTalley ããžã®ç±³åœç¹èš±ç¬¬5,633,272å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«é瀺ãããããã«ãã³ãã·ãã¯ä»¥äžã®æ§é ãæããã
ã¯ããªãã·ã²ããŒãŒ1(COX-1)以äžã«ã·ã¯ããªãã·ã²ããŒãŒ2(COX-2)ãé«åºŠã«éžæçã«é»å®³ãããæçšãªæççå€ãé®çå€ããã³è§£ç±å€ãšããŠè©²ç¹èš±ã«é瀺ãããŠãããåèšã®ç±³åœç¹èš±5,633,272å·ã¯ãŸããé å€ããã³ã«ãã»ã«å€ãªã©ã®çµå£æäžå¯èœè£œå€ãå«ããããã
ååç©ãæäžããããã®è£œå€ã«å¯Ÿããäžè¬çãªåŒçšããŸãå«ãã
ãã«ãã³ãã·ãã®æ°Žæº¶æ§ã¯å€§å€äœããäŸãã°ãDionne (1999)"COX-2é»å®³å€-IBCäŒè°ã1999幎4æ12-13æ¥ãç±³åœã³ãã©ãå·ãã«ãªãã©ã«ãã¢å·",IDrugs, 2(7), 664-666ãåç
§ã®äºã
ç±³åœç¹èš±ç¬¬5,576,014(æ¬é¡ã«åŒçšããŠæŽçšãã)ã¯ãäœãæåæ§ãæããç³è³ªãé«ãæ
åæ§ãæããç³è³ªãšå ±ã«é ç²ããŠé¡ç²ã圢æãããã€ãã§ãããå§çž®ããŠæåç©ãšããã湿åŒé ç²æ³ã«ãã補é ããå£è å 溶解åå§çž®æåç©ãé瀺ããŠãããåŸãããæåç©ã¯è¬ç©ãçµã¿èŸŒãããšãå¯èœã§ãããå£è å ã§æ¥éãªåŽ©å£ãšæº¶è§£ã瀺ããã補é ãšé éã®éã«ç Žæããªãæ§ã«ååãªåŒ·åºŠãç¶æããŠãããšèšãããŠãããç±³åœç¹èš±ç¬¬5,576,014ã®å§çž®
æåç©ã¯ãäžè¬çã«ç³é¡ãªã©ã®æ äœææãšå ±ã«çšããéåžžãåŸæ¶²äžã«å«ãŸãã氎以å€ã«ã¯æ°Žãå¿ èŠãšããªãã§å£è å ã«ãããè¬ç©ã®æ¥éãªæº¶è§£ãŸãã¯åæ£ã䌎ããæ¥éãªåŽ©å£ã瀺ã"é溶é (fast-melt tablet)"ãšããŠç¥ããã補å€ã®1ã€ã§ããããããé å€ã«è£œå€åã
ãè¬ç©ã¯å®¹æã«é£²ã¿èŸŒãããšãã§ããã
åæ§ãæããç³è³ªãšå ±ã«é ç²ããŠé¡ç²ã圢æãããã€ãã§ãããå§çž®ããŠæåç©ãšããã湿åŒé ç²æ³ã«ãã補é ããå£è å 溶解åå§çž®æåç©ãé瀺ããŠãããåŸãããæåç©ã¯è¬ç©ãçµã¿èŸŒãããšãå¯èœã§ãããå£è å ã§æ¥éãªåŽ©å£ãšæº¶è§£ã瀺ããã補é ãšé éã®éã«ç Žæããªãæ§ã«ååãªåŒ·åºŠãç¶æããŠãããšèšãããŠãããç±³åœç¹èš±ç¬¬5,576,014ã®å§çž®
æåç©ã¯ãäžè¬çã«ç³é¡ãªã©ã®æ äœææãšå ±ã«çšããéåžžãåŸæ¶²äžã«å«ãŸãã氎以å€ã«ã¯æ°Žãå¿ èŠãšããªãã§å£è å ã«ãããè¬ç©ã®æ¥éãªæº¶è§£ãŸãã¯åæ£ã䌎ããæ¥éãªåŽ©å£ã瀺ã"é溶é (fast-melt tablet)"ãšããŠç¥ããã補å€ã®1ã€ã§ããããããé å€ã«è£œå€åã
ãè¬ç©ã¯å®¹æã«é£²ã¿èŸŒãããšãã§ããã
æ¬é¡ãšåäžã®è²å人ã«è²æž¡ãããåœéç¹èš±å
¬é第WO01/41761å·ã¯ãå³å¹æ§ãæããçµå£æäžå¯èœãªãã«ãã³ãã·ãçµæç©ãé瀺ããŠããã該æ现æžã«é瀺ãããŠããçµæç©ã«ã¯ãå£è
å
厩å£åçµæç©ã¯ç¡ãã
æ¬é¡ãšåäžã®è²å人ã«è²æž¡ãããåœéç¹èš±å
¬é第WO/15885å·ã¯ã(a) é«ãæåæ§ã®ç³è³ªãå«ãã§ãªãçµåå€ãšå
±ã«éžæçã·ã¯ããªãã·ã²ããŒãŒ2é»å®³å€ã湿åŒé ç²ããã¹ããã
ãããã³ (b)äœãæåæ§ã®ç³è³ªãè¬ç©ã«æ··åããŠé¡ç²ã圢æãããã¹ãããããå«ãã§ãªãéžæçã·ã¯ããªãã·ã²ããŒãŒ2é»å®³å€ã®é溶çµæç©ã®è£œé æ³ãé瀺ããŠãããé ç²å®äº
åŸã颚å³å€ãŸãã¯çå³å€ãªã©ã®è¿œå ã®å»è¬å賊圢å€ãå ããäºãã§ããã
ãããã³ (b)äœãæåæ§ã®ç³è³ªãè¬ç©ã«æ··åããŠé¡ç²ã圢æãããã¹ãããããå«ãã§ãªãéžæçã·ã¯ããªãã·ã²ããŒãŒ2é»å®³å€ã®é溶çµæç©ã®è£œé æ³ãé瀺ããŠãããé ç²å®äº
åŸã颚å³å€ãŸãã¯çå³å€ãªã©ã®è¿œå ã®å»è¬å賊圢å€ãå ããäºãã§ããã
ããšãç³é¡ããã³/ãŸãã¯çå³å€ããã³/ãŸãã¯é¢šå³å€ãå«ããã®ã§ãã£ãŠããçµæç©äžã®æŽ»æ§è¬ã®ååšã«ç±æ¥ããäžå¿«ãªå³ã¯ãå€ãã®å£è
å
厩å£åçµæç©ã«é¢é£ããåé¡ã§ãããäžè¬çã«ãç¹å®ã®å£è
å
厩å£å補å€ã«ååšãã掻æ§è¬ã®éãæžå°ããã«ãããã£ãŠãããã³/ãŸãã¯è¬ç©ã®æ°Žæº¶æ§ãæžå°ããã«ãããã£ãŠã補å€ã®èŠå³ãæžå°ããããã³/ãŸãã¯é
žå³ãæžå°ãããäŸãã°ãLieberman ã(1989)ã®ãPharmaceutical Dosage Forms: Tablets Vol.1, pp.381. Marcel Dekker, New York ãåç
§ã®äºãåŸã£ãŠã倧å€äœã氎溶æ§ãšæ¯èŒçäœãæäžå¿
èŠéãæããè¬å€ã§ãããã«ãã³ãã·ãã¯ãå£è
å
厩å£åçµæç©ãšããŠè£œå€åãããå Žåã蚱容ããããããããã¯æªããšããããããäžçšåºŠã«äžå¿«ãªå®èœçæ§è³ªãæãããšæåŸ
ããããããããªãããé©ãã¹ãããšã«ããã«ãã³ãã·ãã¯ãšãããäžå¿«ãªå³ãæãããã«ãã³ãã·ããé溶çµæç©ãšããŠè£œå€åãããå Žåããã®ç¹å¥ãªå³ã®åé¡ãçããããšãä»åèŠåºãããåŸã£ãŠãå容ã§ããå®èœçæ§è³ªãæããå£è
å
厩å£åãã«ãã³ãã·ãçµæç©ã®å¿
èŠæ§ã¯äŸç¶ãšããŠååšããã
äžç床ãŸãã¯é«åºŠã«æ°Žæº¶æ§ã®ããè¬ç©ã®å£è
å
溶解ãé»å®³ããããšã«ããäœçšããå³ãã¹ãã³ã°æè¡ããå»è¬è£œå€ã«é©çšãããŠãããäŸãã°ãåèšã®Lieberman ã(1989)ãåç
§ã®äºããã®å Žåã«ãããŠãæ¶å管äžã«å
¥ãåã«å£äžã§æº¶è§£ããè¬ç©ã®éã®æžå°ã«èµ·å ããå³ã®æ¹åãèãããããããããªãããããšããšæ¥µç«¯ã«äœããã«ãã³ãã·ãã®æ°Žæº¶æ§ãèæ
®ããŠãããã«ãã³ãã·ãã®å£è
å
溶解ã®ãããªãæžå°ããå®èœçæ§è³ªã®æ¹åããããããšã¯äºæãããªãã£ããããã«ããã«ãã³ãã·ãã®æ°Žæº¶æ§ã®ãããªãæžå°ããå容ã§ããªãæ²»çéå§ã®é
延ãå°ããšäºæ³ãããã
ããããªãããé©ãã¹ãããšã«ãæã
ã¯ãå®èœçæ§è³ªã®æ¹åã瀺ãçµæç©ã§ãããªãããæ²»çå¹æã®æ¥éãªäœçšéå§ã瀺ãå£è
å
厩å£åãã«ãã³ãã·ãçµæç©ã®è£œé æ¹æ³ãèŠåºããã
çºæã®æŠèŠ
åŸã£ãŠãå£è å 厩å£åãã«ãã³ãã·ãçµæç©(äŸãã°ãé溶é )ã®è£œé æ³ã§ãã£ãŠããã«ãã³ãã·ãã埮ç²åç¶ã§æäŸããã¹ãããïŒæ¥éãªå£è å 溶解ã瀺ãå°ãªããšãïŒã€ã®è¬åŠçã«èš±å®¹ããã賊圢å€ãšçå³æã容åšäžã®æ°Žã«æº¶è§£ããã¹ãã¬ãŒæ¶²ãäœæããã¹ãããïŒã¹ãã¬ãŒæ¶²ãçšããŠãã«ãã³ãã·ããæµåå±€é ç²ããæé çšæ··åç©ãäœæããã¹ãããïŒããã³ãæé çšæ··åç©ãå§çž®ããŠé å€ãäœæããã¹ããããå«ãã§ãªã補é æ³ãæäŸããããæ¬çºæã®æ¹æ³ã«ãããŠãæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è³Šåœ¢å€ãã奜
ãŸããã¯ãå·¥çšã®å®äºæã«ãé å€ééã®çŽ50%ããçŽ99%ãã奜ãŸããã¯çŽ50%ããçŽ90%ãããããŠããããã«å¥œãŸããã¯çŽ50%ããçŽ80%ã該賊圢å€ãå«ããããªç·éã§æº¶è§£ããã
çºæã®æŠèŠ
åŸã£ãŠãå£è å 厩å£åãã«ãã³ãã·ãçµæç©(äŸãã°ãé溶é )ã®è£œé æ³ã§ãã£ãŠããã«ãã³ãã·ãã埮ç²åç¶ã§æäŸããã¹ãããïŒæ¥éãªå£è å 溶解ã瀺ãå°ãªããšãïŒã€ã®è¬åŠçã«èš±å®¹ããã賊圢å€ãšçå³æã容åšäžã®æ°Žã«æº¶è§£ããã¹ãã¬ãŒæ¶²ãäœæããã¹ãããïŒã¹ãã¬ãŒæ¶²ãçšããŠãã«ãã³ãã·ããæµåå±€é ç²ããæé çšæ··åç©ãäœæããã¹ãããïŒããã³ãæé çšæ··åç©ãå§çž®ããŠé å€ãäœæããã¹ããããå«ãã§ãªã補é æ³ãæäŸããããæ¬çºæã®æ¹æ³ã«ãããŠãæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è³Šåœ¢å€ãã奜
ãŸããã¯ãå·¥çšã®å®äºæã«ãé å€ééã®çŽ50%ããçŽ99%ãã奜ãŸããã¯çŽ50%ããçŽ90%ãããããŠããããã«å¥œãŸããã¯çŽ50%ããçŽ80%ã該賊圢å€ãå«ããããªç·éã§æº¶è§£ããã
æ¬æ¹æ³ã¯ãææã«ãããåèšæµåå±€é ç²ã¹ãããã®åã«æ°Žããã³/ãŸãã¯ã¹ãã¬ãŒæ¶²ã
å ç±ããã¹ããããå«ããæ¬æ¹æ³ã¯ãå§çž®ã®åã«æé çšæ··åç©ãžå°ãªããšãïŒã€ã®è¬åŠçã«èš±å®¹ããã厩å£å€ãæ·»å ããã¹ããããããã«å«ãã
å ç±ããã¹ããããå«ããæ¬æ¹æ³ã¯ãå§çž®ã®åã«æé çšæ··åç©ãžå°ãªããšãïŒã€ã®è¬åŠçã«èš±å®¹ããã厩å£å€ãæ·»å ããã¹ããããããã«å«ãã
æ¬æ¹æ³ã¯ãæµåå±€é ç²ã¹ãããã®åã«ãå°ãªããšãïŒã€ã®è¬åŠçã«èš±å®¹ããã湿最å€ãŸãã¯ããã湿最å€ã®æ°Žæº¶æ¶²ããæ°ŽãŸãã¯ã¹ãã¬ãŒæ¶²ã«æº¶è§£ããã¹ããããææã«ããããã«å«ãã
æããããªãããšã«ãæã
ã¯ãçå³æã®é¡ç²å
æ·»å ã«ãããé¡ç²å€æ·»å ãšæ¯èŒããŠãå®èœçæ§è³ªã®æ¹åã瀺ããã«ãã³ãã·ãé溶é ãåŸãããããšãèŠåºããã
ãããæ¹æ³ã«ãã補é ãããçµæç©ã¯ãæ¬çºæã®å®æœæ æ§ãè¡šããäŸãã°ãæ²»ççæå¹éã®åŸ®ç²åç¶ãã«ãã³ãã·ããæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹
ããã賊圢å€ããã³çå³æãå«ãã§ãªãå£è å 厩å£åçµæç©ããŸãæäŸããããæ¥éãªå£è å 溶解ã瀺ã賊圢å€ããã³çå³æã¯ããã«ãã³ãã·ãç²åãšå¯æ¥ãªäŒåãããŠãããæ¬çµæç©ã¯å®èœçã«èš±å®¹ããããããŠãæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠç
ã«èš±å®¹ããã賊圢å€ããçµæç©ã®ééã®çŽ50%ããçŽ99%ã®ã奜ãŸããã¯çŽ50%ããçŽ95%ã®ãããã«å¥œãŸããã¯çŽ50%ããçŽ90%ã®ããããŠããããã«å¥œãŸããã¯çŽ50%ããçŽ80%ã®ç·éã§ååšããã
ãããæ¹æ³ã«ãã補é ãããçµæç©ã¯ãæ¬çºæã®å®æœæ æ§ãè¡šããäŸãã°ãæ²»ççæå¹éã®åŸ®ç²åç¶ãã«ãã³ãã·ããæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹
ããã賊圢å€ããã³çå³æãå«ãã§ãªãå£è å 厩å£åçµæç©ããŸãæäŸããããæ¥éãªå£è å 溶解ã瀺ã賊圢å€ããã³çå³æã¯ããã«ãã³ãã·ãç²åãšå¯æ¥ãªäŒåãããŠãããæ¬çµæç©ã¯å®èœçã«èš±å®¹ããããããŠãæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠç
ã«èš±å®¹ããã賊圢å€ããçµæç©ã®ééã®çŽ50%ããçŽ99%ã®ã奜ãŸããã¯çŽ50%ããçŽ95%ã®ãããã«å¥œãŸããã¯çŽ50%ããçŽ90%ã®ããããŠããããã«å¥œãŸããã¯çŽ50%ããçŽ80%ã®ç·éã§ååšããã
æ¬èšè¿°ã«ãããŠã"å¯æ¥ãªäŒå(intimate association)"ã¯ãäŸãã°ãæ¥éãªå£è
å
溶解ã瀺ã賊圢å€ãšæ··åãããã«ãã³ãã·ããæ¥éãªå£è
å
溶解ã瀺ã賊圢å€ã«åã蟌ãŸãããããã¯çµã¿èŸŒãŸãããã«ãã³ãã·ããæ¥éãªå£è
å
溶解ã瀺ã賊圢å€ã®ç²åã«ã³ãŒãã£ã³ã°ã圢æãããã«ãã³ãã·ã(ãããã¯éããŸãåæ§)ããããŠãæ¥éãªå£è
å
溶解ã瀺ã賊圢å€å
šäœã«æž¡ããã«ãã³ãã·ãã®å®è³ªçã«åäžãªåæ£ãå«ãããããå¯æ¥ãªäŒåäœã¯ãåèšã«èšèŒã®æ¹æ³ã«ããäŸèšŒãšããŠäœæããïŒããã«ä»£ããŠããããã¯ããã«å ããŠããããå¯æ¥ãªäŒåäœãäœæããä»ã®æ段ãæ¬çºæã®æ¹æ³ã«äœ¿çšããããšãã§ããã
æ¥éãªå£è
å
溶解ã瀺ã賊圢å€ãšå¯æ¥ãªäŒåããããã«ãã³ãã·ãã¯ãŸããæ¬æ现æžã«ãããŠ"ãã«ãã³ãã·ãè€åç©ïŒcompositeïŒ"ãšãåŒã¶ãè€æ°ã®æåãå«ãæ··åç©ãŸãã¯
å»è¬çµæç©ã«é¢é£ãããæ¬æ现æžã«ããã"å®è³ªçã«åäžãª"ãšããçšèªã¯ãæåãååã«æ··åãããŠããããã«ãåæåãåé¢ããå±€ã圢æãããçµæç©äžã§æ¿åºŠåŸé ã圢æããŠããªãããšãæå³ãããçè«ã«æããããããã§ã¯ãªãããæ¬çºæã®æ¹æ³ããã³çµæç©ã«ãããŠããã«ãã³ãã·ãã«å¯ŸããŠæ¥éãªå£è å 溶解ã瀺ã賊圢å€ã®æ¯èŒçé«ãæ¯çããã³/ãŸãã¯æ¥éãªå£è å 溶解ã瀺ã賊圢å€ãšãã«ãã³ãã·ãã®å¯æ¥ãªäŒåã«ãããå®èœçæ§
質ãæ¹åããããã«ãã³ãã·ãè€åç©ãäœæãããã
å»è¬çµæç©ã«é¢é£ãããæ¬æ现æžã«ããã"å®è³ªçã«åäžãª"ãšããçšèªã¯ãæåãååã«æ··åãããŠããããã«ãåæåãåé¢ããå±€ã圢æãããçµæç©äžã§æ¿åºŠåŸé ã圢æããŠããªãããšãæå³ãããçè«ã«æããããããã§ã¯ãªãããæ¬çºæã®æ¹æ³ããã³çµæç©ã«ãããŠããã«ãã³ãã·ãã«å¯ŸããŠæ¥éãªå£è å 溶解ã瀺ã賊圢å€ã®æ¯èŒçé«ãæ¯çããã³/ãŸãã¯æ¥éãªå£è å 溶解ã瀺ã賊圢å€ãšãã«ãã³ãã·ãã®å¯æ¥ãªäŒåã«ãããå®èœçæ§
質ãæ¹åããããã«ãã³ãã·ãè€åç©ãäœæãããã
ãšãããæçšãªæ¬çºæã®å£è
å
厩å£åçµæç©ã¯ã飲ææ°ŽãŸãã¯ä»ã®æ¶²äœãå¿
èŠãšããªãã§å£è
å
ã§æº¶è§£ããæ¥é厩å£åçµå£å€ã§ãã(äŸãã°ãé溶é )ãæ¬æ现æžã«ãããŠäœ¿çšããã"é溶é (fast-melt)"ãšããçšèªã¯ãæ
äœã«ãã圢æããããããªãã¯ã¹äžã«æŽ»æ§æ
åãŸãã¯è¬ç©ãååžãŸãã¯åæ£ããé å€ãªã©ã®çµæç©ã®ããšãèšãããã®çµæç©ã¯ã被éšè ã«çµæç©ãçµå£æäžããããšã«ãããå£è å ã§åŽ©å£ããã€ãã§ãå¥äžã«ããæ¶å管ã«å ¥ãã次ãã§åžåããããã«è¬ç©ãäžè¬çã«åŸ®ç²å圢ã§æŸåºããã"å£è "ãšããçšèªã¯ãå£è ååº(æ¯ãæ¯èã®åéšã®å£è éšå)ã®ã¿ã§ã¯ãªããèäžããã³èäžéšãå«ãå£è åéšå šäœãå«ãã
åãŸãã¯è¬ç©ãååžãŸãã¯åæ£ããé å€ãªã©ã®çµæç©ã®ããšãèšãããã®çµæç©ã¯ã被éšè ã«çµæç©ãçµå£æäžããããšã«ãããå£è å ã§åŽ©å£ããã€ãã§ãå¥äžã«ããæ¶å管ã«å ¥ãã次ãã§åžåããããã«è¬ç©ãäžè¬çã«åŸ®ç²å圢ã§æŸåºããã"å£è "ãšããçšèªã¯ãå£è ååº(æ¯ãæ¯èã®åéšã®å£è éšå)ã®ã¿ã§ã¯ãªããèäžããã³èäžéšãå«ãå£è åéšå šäœãå«ãã
æ¬æ现æžã«ãããŠã"å®èœçã«èš±å®¹ããã"補å€ãŸãã¯"蚱容ãããå®èœçæ§è³ª"ãæãã補å€ã¯ãæ²»çå€ã®ååæäžéãäŸçµŠããéã«ãããå£è
å
çžäºäœçšã«ãããŠãäŸãã°ãã被éšè
ã®å€§å€æ°ã«ãã£ãŠç¥èŠããããããããã¯ä»¥äžã«èšèŒãããããªãã©ã€ã³ãå³èŠè©äŸ¡è©Šéšã®åæã«ãã枬å®ããããããªãèããèŠãå³ãªã©ã®é床ã«äžå¿«ãªå³ãã«ããããã³å£åœãããæããªãã
æ¬çºæã®æ¹æ³ãšçµæç©ã«ãããæ¥éãªäœçšéå§æ§ãšæ²»çå¹æã蚱容ãããªãçšåºŠã«ç ç²ã«ããããšãªãããã«ãã³ãã·ãã®èš±å®¹ãããªãå®èœçæ§è³ªãå
æãããããšãèŠåºããããåŸã£ãŠãåœè©²æè¡åéã«ãããèããé²æ©ã«ãããŠãä»åããã«ãã³ãã·ããå®èœçã«èš±å®¹ãããé溶補å€ã§æäŸããããæ¬çºæã®çµæç©ã®ç¹å¥ãªå©ç¹ã¯ãå®èœçæ§è³ªã®æ¹åã蚱容ãããæ²»çäœçšéå§æ§ãæããããšã§ããããããŠãããçµæç©ã¯ãæ¬æ现æžã«èšèŒã®æ¹æ³ã§å¹çãã補é ããããšãã§ããã
çºæã®è©³çŽ°ãªèª¬æ
æ¬çºæã®ç¹å¥ãªå®æœæ æ§ã¯ãæ²»ççæå¹éã®åŸ®ç²åç¶ãã«ãã³ãã·ããæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢å€ããã³çå³æãå«ãã§ãªããçµå£
é溶çµæç©ã§ãããæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢
å€ããã³çå³æã¯ãçµæç©äžã®ãã«ãã³ãã·ãç²åãšå¯æ¥ãªäŒåãããŠããã
çºæã®è©³çŽ°ãªèª¬æ
æ¬çºæã®ç¹å¥ãªå®æœæ æ§ã¯ãæ²»ççæå¹éã®åŸ®ç²åç¶ãã«ãã³ãã·ããæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢å€ããã³çå³æãå«ãã§ãªããçµå£
é溶çµæç©ã§ãããæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢
å€ããã³çå³æã¯ãçµæç©äžã®ãã«ãã³ãã·ãç²åãšå¯æ¥ãªäŒåãããŠããã
1ã€ã®é¢é£ããå®æœæ
æ§ã«ãããŠãçµæç©ã¯å®èœçã«èš±å®¹ãããæ¥éãªå£è
å
溶解ã瀺
ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢å€ã¯ãçµæç©ééã®çŽ50%ãã99%ã®ç·éã§
ååšãããããŠãã被éšè ã®å£è å ã«çœ®ããåŸãçµæç©ã¯çŽ60ç§ä»¥å ã«ã奜ãŸããã¯çŽ30ç§ä»¥å ã«ããããŠããã«å¥œãŸããã¯çŽ15ç§ä»¥å ã«åŽ©å£ããã
ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢å€ã¯ãçµæç©ééã®çŽ50%ãã99%ã®ç·éã§
ååšãããããŠãã被éšè ã®å£è å ã«çœ®ããåŸãçµæç©ã¯çŽ60ç§ä»¥å ã«ã奜ãŸããã¯çŽ30ç§ä»¥å ã«ããããŠããã«å¥œãŸããã¯çŽ15ç§ä»¥å ã«åŽ©å£ããã
ãã1ã€ã®é¢é£ããå®æœæ
æ§ã«ãããŠãç±³åœè¬å±æ¹24 in vitro 厩å£è©ŠéšTest Number 701 ã«æºæ ããå Žåãæ¬çµæç©ã¯çŽ300ç§æªæºã®ã奜ãŸããã¯çŽ200ç§æªæºã®ããããŠãã
ã«å¥œãŸããã¯çŽ100ç§æªæºã®åŽ©å£æéã瀺ãã
ã«å¥œãŸããã¯çŽ100ç§æªæºã®åŽ©å£æéã瀺ãã
ããã«ãã1ã€ã®é¢é£ããå®æœæ
æ§ã«ãããŠããã被éšè
ãžã®çµæç©ã®æäžã«ãããçµ
å£æäžã®çŽ0ïŒ5æé以å ã«ã奜ãŸããã¯0ïŒ3æé以å ã«ãæ²»çå¹æã®ããã®ãã«ãã³ãã·ãéŸå€æ¿åºŠãåŸãããã"æ²»çå¹æã®ããã®éŸå€æ¿åºŠ"ã¯ããã«ãã³ãã·ãã®æäžç®çã®ç¹å®ã®å åã«å¯ŸããŠæ²»çå¹æãçºæ®ããè¡æž äžã®æå°ãã«ãã³ãã·ãæ¿åºŠãæå³ãããäžè¬çã«ããã®éŸå€æ¿åºŠã¯ãå°ãªããšãçŽ20ng/ml ã§ãããäŸãã°çŽ25ng/mlããçŽ75ng/mlã§ããã
å£æäžã®çŽ0ïŒ5æé以å ã«ã奜ãŸããã¯0ïŒ3æé以å ã«ãæ²»çå¹æã®ããã®ãã«ãã³ãã·ãéŸå€æ¿åºŠãåŸãããã"æ²»çå¹æã®ããã®éŸå€æ¿åºŠ"ã¯ããã«ãã³ãã·ãã®æäžç®çã®ç¹å®ã®å åã«å¯ŸããŠæ²»çå¹æãçºæ®ããè¡æž äžã®æå°ãã«ãã³ãã·ãæ¿åºŠãæå³ãããäžè¬çã«ããã®éŸå€æ¿åºŠã¯ãå°ãªããšãçŽ20ng/ml ã§ãããäŸãã°çŽ25ng/mlããçŽ75ng/mlã§ããã
æ²»çå¹æã®ããã®éŸå€æ¿åºŠãæäŸãããã«ãã³ãã·ãã®éã¯ããšããããæ²»ç被éšè
ã®äœéã«äŸåããŠããããšã¯ç解ãããã§ãããã被éšè
ãå°å
ãŸãã¯å°åç©(äŸãã°ãç¬)ã§ããå ŽåãäŸãã°ãçŽ1mgãã100mgã®æ¯èŒçäœãæ²»ççæå¹ç¯å²ã®ãã«ãã³ãã·ãã®éããéŸå€æ¿åºŠããã³Cmaxåºæºã«å¯Ÿå¿ããè¡æž
æ¿åºŠãæäŸãããšæãããã被éšè
ãæ人ãŸãã¯å€§åç©(äŸãã°ããŠã)ã®å Žåããã«ãã³ãã·ãã®æãŸããè¡æž
æ¿åºŠã¯ããã«ãã³ãã·ãã®æ¯èŒç倧ããæäžéãå¿
èŠãšãããšæããããæ人ã«é¢ããŠã¯ãæãŸããè¡æž
æ¿åºŠãæäŸããæ¬çºæã®çµæç©ã«ãããäžæãããã®ãã«ãã³ãã·ãã®é©åãªéã¯ãäžè¬çã«ãçŽ5mgããçŽ40mgã§ããã
æ¬çºæã®ãã1ã€ã®é¢é£ããå®æœæ
æ§ã«ãããŠããã被éšè
ãžã®æ¬çµæç©ã®æäžã¯ãçŽ100ng/ml以äžã®æé«è¡æž
äžæ¿åºŠ(Cmax)ããã³/ãŸãã¯çŽ5æé以äžã®ã奜ãŸããã¯ãçŽ4æé以äžã®ããããŠããã«å¥œãŸããã¯çŽ3æé以äžã®æé«è¡æž
äžæ¿åºŠå°éæé(Tmax)ãããã
ãã
æ¬çºæã®çµæç©ã®æå
æ¬çºæã®çµæç©ã¯ã掻æ§æåãšããŠã®ãã«ãã³ãã·ããšãæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢å€ãå«ããææã«ãããæ¬çºæã®çµæç©ã¯ã氎溶
æ§æ»æ²¢å€ãé氎溶æ§æ»æ²¢å€ã厩å£å€ãæµåä¿é²å€ãçå³æã颚å³å€ãçè²å€ãªã©ã®ïŒçš®é¡ä»¥äžã®è¿œå ã®è¬åŠçã«èš±å®¹ãããå»è¬å賊圢å€ãå«ãããšãã§ããããããã«éå®ãããªãããããä»»æã®è¿œå ã®æåã¯ãæ¬çµæç©ã®ä»ã®æåãšç©ççããã³ååŠçã«é©åããªããã°ãªããªããããã€å容è ã«æ害ã§ãã£ãŠã¯ãªããªãã
ãã«ãã³ãã·ã
æ¬çºæã®æ¹æ³ãšçµæç©ã¯ããšããã掻æ§è¬ãšããŠã®ãã«ãã³ãã·ãã«é©ããŠããã埮ç²åç¶ãã«ãã³ãã·ãã®è£œé æ³ã¯ããèªäœç¥ãããŠãããäŸãã°ãåèšã®ç±³åœç¹èš±ç¬¬5ïŒ474ïŒ995å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«èšèŒãããŠãããéèŠãªããšã«ã¯ãåºäœç¶ãã«ãã³
ãã·ãã®ã©ãã§ããäŸãšããŠåœéç¹èš±åºé¡ç¬¬98/06708å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«èšèŒã®ãã®ãªã©ã¯ãæ¬çºæã®æ¹æ³ãšçµæç©ã«äœ¿çšããããšãã§ããã
ãã
æ¬çºæã®çµæç©ã®æå
æ¬çºæã®çµæç©ã¯ã掻æ§æåãšããŠã®ãã«ãã³ãã·ããšãæ¥éãªå£è å 溶解ã瀺ãå°ãªããšã1çš®é¡ã®è¬åŠçã«èš±å®¹ããã賊圢å€ãå«ããææã«ãããæ¬çºæã®çµæç©ã¯ã氎溶
æ§æ»æ²¢å€ãé氎溶æ§æ»æ²¢å€ã厩å£å€ãæµåä¿é²å€ãçå³æã颚å³å€ãçè²å€ãªã©ã®ïŒçš®é¡ä»¥äžã®è¿œå ã®è¬åŠçã«èš±å®¹ãããå»è¬å賊圢å€ãå«ãããšãã§ããããããã«éå®ãããªãããããä»»æã®è¿œå ã®æåã¯ãæ¬çµæç©ã®ä»ã®æåãšç©ççããã³ååŠçã«é©åããªããã°ãªããªããããã€å容è ã«æ害ã§ãã£ãŠã¯ãªããªãã
ãã«ãã³ãã·ã
æ¬çºæã®æ¹æ³ãšçµæç©ã¯ããšããã掻æ§è¬ãšããŠã®ãã«ãã³ãã·ãã«é©ããŠããã埮ç²åç¶ãã«ãã³ãã·ãã®è£œé æ³ã¯ããèªäœç¥ãããŠãããäŸãã°ãåèšã®ç±³åœç¹èš±ç¬¬5ïŒ474ïŒ995å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«èšèŒãããŠãããéèŠãªããšã«ã¯ãåºäœç¶ãã«ãã³
ãã·ãã®ã©ãã§ããäŸãšããŠåœéç¹èš±åºé¡ç¬¬98/06708å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«èšèŒã®ãã®ãªã©ã¯ãæ¬çºæã®æ¹æ³ãšçµæç©ã«äœ¿çšããããšãã§ããã
æ¬çºæã®ãã«ãã³ãã·ãåäœè£œå€ã¯ãçŽ1mgããçŽ100mgã奜ãŸããã¯çŽ5mgããçŽ50mg
ã®æ²»ççæå¹éã®ãã«ãã³ãã·ããå«ããæ¬çºæã®çµæç©ã¯ã埮ç²åç¶ã®ãã«ãã³ãã·ããå«ããäŸãã°ããªã³ã°ãŸãã¯ã°ã©ã€ã³ãã£ã³ã°ã«ããããããã¯æº¶æ¶²ããã®æåºã«ããçæãããäžæ¬¡ãã«ãã³ãã·ãç²åã¯ãåéããŠäºæ¬¡éåç²åã圢æããããšãã§ããã
æ¬æ现æžã§çšãã"ç²ååŸ"ãšããçšèªã¯ãç¹èšããªãéããæé·åŸã«ãããäžæ¬¡ç²åã®çŽåŸããããç²ååŸã¯ããã«ãã³ãã·ãã®èšåºçæçšæ§ã«åœ±é¿ããéèŠãªãã©ã¡ãŒã¿ãŒã§ãããšèãããããåŸã£ãŠã1ã€ã®å®æœæ æ§ã«ãããŠããã«ãã³ãã·ã補å€ã¯ãD90ç²ååŸãçŽ75ÎŒmæªæºã§ãããããªãã«ãã³ãã·ãç²ååŸã®ååžãæãããæ¬æ现æžã«ãããŠ"D90
ç²ååŸ"ã¯ãç²åã®ééã§90%ããã®ç²ååŸãããæ倧åŸã«ãããŠå°ãããããªç²ååŸãšããŠå®çŸ©ããããããã«ããããã¯ãã®ä»£ããã«ãæ¬çºæã®è£œå€ã«ããããã«ãã³ãã·ãç²åã¯ã奜ãŸããã¯ãçŽ1ÎŒmããçŽ10ÎŒmãæã奜ãŸããã¯çŽ5ÎŒmããçŽ7ÎŒmã®å éå¹³åç²
ååŸãæããã
æ¥éãªå£è å 溶解ã瀺ãå»è¬å賊圢å€
æ¥éãªå£è å 溶解ã瀺ãé©åãªå»è¬å賊圢å€ã¯ãäŸãã°ãAnsel et al. (1995) Pharmceutical Dosage Forms and Drug Delivery Systems 6th Ed, pp. 228. Williams & Wilkins Baltimore ã«èšèŒãããŠãããããªãæ°Žã«æº¶è§£ã§ãããè¯ã溶ããããããã¯å€§å€è¯
ã溶ããè¬åŠçã«èš±å®¹ãããå»è¬å賊圢å€ã§ããã奜ãŸããã¯ããããå»è¬åæ·»å ç©ã¯ãçå³ãæãããæ¬çºæã®çµæç©ããã³æ¹æ³ã«ããã䜿çšã®ããã®æ¥éãªå£è å 溶解ã瀺ãã賊圢å€ã®çŸåšå¥œãŸããã¯ã©ã¹ã¯ãçæ°Žåç©ã§ãããæ¥éãªå£è å 溶解ã瀺ããšããã奜ãŸãã賊圢å€ã¯ãäœãæåæ§ããã³é«ãæåæ§ã®äž¡æ¹ã®ç³è³ªãå«ãç³è³ªã§ããã
ã®æ²»ççæå¹éã®ãã«ãã³ãã·ããå«ããæ¬çºæã®çµæç©ã¯ã埮ç²åç¶ã®ãã«ãã³ãã·ããå«ããäŸãã°ããªã³ã°ãŸãã¯ã°ã©ã€ã³ãã£ã³ã°ã«ããããããã¯æº¶æ¶²ããã®æåºã«ããçæãããäžæ¬¡ãã«ãã³ãã·ãç²åã¯ãåéããŠäºæ¬¡éåç²åã圢æããããšãã§ããã
æ¬æ现æžã§çšãã"ç²ååŸ"ãšããçšèªã¯ãç¹èšããªãéããæé·åŸã«ãããäžæ¬¡ç²åã®çŽåŸããããç²ååŸã¯ããã«ãã³ãã·ãã®èšåºçæçšæ§ã«åœ±é¿ããéèŠãªãã©ã¡ãŒã¿ãŒã§ãããšèãããããåŸã£ãŠã1ã€ã®å®æœæ æ§ã«ãããŠããã«ãã³ãã·ã補å€ã¯ãD90ç²ååŸãçŽ75ÎŒmæªæºã§ãããããªãã«ãã³ãã·ãç²ååŸã®ååžãæãããæ¬æ现æžã«ãããŠ"D90
ç²ååŸ"ã¯ãç²åã®ééã§90%ããã®ç²ååŸãããæ倧åŸã«ãããŠå°ãããããªç²ååŸãšããŠå®çŸ©ããããããã«ããããã¯ãã®ä»£ããã«ãæ¬çºæã®è£œå€ã«ããããã«ãã³ãã·ãç²åã¯ã奜ãŸããã¯ãçŽ1ÎŒmããçŽ10ÎŒmãæã奜ãŸããã¯çŽ5ÎŒmããçŽ7ÎŒmã®å éå¹³åç²
ååŸãæããã
æ¥éãªå£è å 溶解ã瀺ãå»è¬å賊圢å€
æ¥éãªå£è å 溶解ã瀺ãé©åãªå»è¬å賊圢å€ã¯ãäŸãã°ãAnsel et al. (1995) Pharmceutical Dosage Forms and Drug Delivery Systems 6th Ed, pp. 228. Williams & Wilkins Baltimore ã«èšèŒãããŠãããããªãæ°Žã«æº¶è§£ã§ãããè¯ã溶ããããããã¯å€§å€è¯
ã溶ããè¬åŠçã«èš±å®¹ãããå»è¬å賊圢å€ã§ããã奜ãŸããã¯ããããå»è¬åæ·»å ç©ã¯ãçå³ãæãããæ¬çºæã®çµæç©ããã³æ¹æ³ã«ããã䜿çšã®ããã®æ¥éãªå£è å 溶解ã瀺ãã賊圢å€ã®çŸåšå¥œãŸããã¯ã©ã¹ã¯ãçæ°Žåç©ã§ãããæ¥éãªå£è å 溶解ã瀺ããšããã奜ãŸãã賊圢å€ã¯ãäœãæåæ§ããã³é«ãæåæ§ã®äž¡æ¹ã®ç³è³ªãå«ãç³è³ªã§ããã
çŸåšå¥œãŸããäœãæåæ§ã®ç³è³ªã¯ãã©ã¯ããŒã¹ããã³ãã³ãããŒã«ã§ãã,
Kibbe (2000) Handbook of Pharmaceutical Excipients, 3rd Ed., Pharmaceutical Press
pp. 324-328ã«èšèŒã®ããã«ããšããããéæ¥å§çž®ç¶ãŸãã¯ç²æ«ç¶ã®ãã³ãããŒã«ã§ãã
ãé«ãæåæ§ã®çŸåšå¥œãŸããç³è³ªã¯ããã«ããŒã¹ããã«ãããŒã«ããã³ãœã«ãããŒã«ãå«ãããããã¯ãç¹å®ã®ãªãªãŽç³ãå Žåã«ããæçšã§ããã䜿çšããããªãªãŽç³ã¯ãå£è äžã§æ¥éãªæº¶è§£ã瀺ãã2å以äžã®åç³æ®åºãããªããã®ã§ããã°ãç¹å®ã®ãã®ã«éå®ãã
ãªãããªãªãŽç³ã䜿çšãããå Žåã2-6åã®åç³æ®åºãããªããã®ã奜ãŸããããªãªãŽç³
ãæ§æããåç³æ®åºã®ã¿ã€ããšçµã¿åããã¯éå®ãããªãããšããã奜ãŸããé«ãæåæ§ã®ç³è³ªã¯ããã«ããŒã¹ããã³ãã«ãããŒã«ã§ãããããã«ãšããã奜ãŸããã¯ããã«ããŒã¹ã§ããã
Kibbe (2000) Handbook of Pharmaceutical Excipients, 3rd Ed., Pharmaceutical Press
pp. 324-328ã«èšèŒã®ããã«ããšããããéæ¥å§çž®ç¶ãŸãã¯ç²æ«ç¶ã®ãã³ãããŒã«ã§ãã
ãé«ãæåæ§ã®çŸåšå¥œãŸããç³è³ªã¯ããã«ããŒã¹ããã«ãããŒã«ããã³ãœã«ãããŒã«ãå«ãããããã¯ãç¹å®ã®ãªãªãŽç³ãå Žåã«ããæçšã§ããã䜿çšããããªãªãŽç³ã¯ãå£è äžã§æ¥éãªæº¶è§£ã瀺ãã2å以äžã®åç³æ®åºãããªããã®ã§ããã°ãç¹å®ã®ãã®ã«éå®ãã
ãªãããªãªãŽç³ã䜿çšãããå Žåã2-6åã®åç³æ®åºãããªããã®ã奜ãŸããããªãªãŽç³
ãæ§æããåç³æ®åºã®ã¿ã€ããšçµã¿åããã¯éå®ãããªãããšããã奜ãŸããé«ãæåæ§ã®ç³è³ªã¯ããã«ããŒã¹ããã³ãã«ãããŒã«ã§ãããããã«ãšããã奜ãŸããã¯ããã«ããŒã¹ã§ããã
æ¬çºæã®çµæç©äžã«ãé«ãæåæ§ã®ç³è³ªãšäœãæ圢æ§ã®ç³è³ªã®äž¡æ¹ãååšããå Žåã蚱容ãããé å€åŒ·åºŠãšè¿
éãªå£è
å
厩å£ã®çµã¿åãããç¶æããã®ã«ãé«ãæåæ§ã®ç³è³ªãšäœãæåæ§ã®ç³è³ªã®ééæ¯ãéèŠã§ãããäœãæåæ§ã®ç³è³ªã®ééã100ã«å¯ŸããŠãé«ã
æåæ§ã®ç³è³ªã®é©åãªæ¯çã¯ãééã§çŽ2ããçŽ20ã§ããã奜ãŸããã¯ééã§çŽ5ããçŽ10ã§ãããããã«å¥œãŸããã¯ééã§çŽ5ããçŽ7ïŒ5ã§ããã
æåæ§ã®ç³è³ªã®é©åãªæ¯çã¯ãééã§çŽ2ããçŽ20ã§ããã奜ãŸããã¯ééã§çŽ5ããçŽ10ã§ãããããã«å¥œãŸããã¯ééã§çŽ5ããçŽ7ïŒ5ã§ããã
æåæ§ã®é«ãç³è³ªãšäœãç³è³ªã®ééæ¯çãçŽ2ïŒ100æªæºã®å Žåãäžè¬çã«ãé å€ã¯ææã®ç¡¬åºŠãéæã§ãããä¿åã茞éãŸãã¯åãæ±ãäžã®ç Žæãå¢å ããããããã¯ãæ圢æ§ã®é«ãç³è³ªãšäœãç³è³ªã®ééæ¯çãçŽ20ïŒ100ãäžåãå Žåãé å€ã¯ç¡¬ããªããããå£è
å ã«ãããææã®æ¥éãªåŽ©å£ã¯åŸãããªãã
å ã«ãããææã®æ¥éãªåŽ©å£ã¯åŸãããªãã
æ¥éãªå£è
å
溶解ã瀺ãïŒçš®é¡ä»¥äžã®å»è¬å賊圢å€ã¯ãäžè¬çã«ãæ¬çºæã®çµæç©äžã«ãçŽ45%ããçŽ95%ã奜ãŸããã¯çŽ50%ããçŽ87%ããããŠããã«å¥œãŸããã¯çŽ55%ããçŽ80%ã®ç·éã§ååšããã
çå³å€
æ¬çºæã®çµæç©ã¯ãïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ãããçå³å€(æ¬æ现æžã§ã¯çå³æãšã
称ãã)ãå«ããå€ãã®å»è¬å賊圢å€ã¯çå³ãæããäºãç解ãããããæ¬æ现æžã«ãã
ãŠã"çå³å€"ãŸãã¯"çå³æ"ãšããçšèªã¯ãéç³è³ªããã³éç³ã¢ã«ã³ãŒã«çå³æã®ããšãèšãããããçå³æã®ééå®çãªäŸã¯ãã¢ã»ã¹ã«ãã¡ã Kãã¢ã¹ãã«ããŒã ããã«ãããŒ
ã«ãããªããŒã ããµãã«ãªã³ããµãã«ãªã³ãããªãŠã ããµã€ã¯ã©ãã³é žãããªãŠã ãããã³ãããã®å¡©ãå«ãã奜ãŸããã¯ãæ¬çºæã®çµæç©äžã«ãçå³æã¯ãçµæç©ééã®0ïŒ05%
ããçŽ10%ã奜ãŸããã¯çŽ0ïŒ5ããçŽ7ïŒ5%ããããŠããã«å¥œãŸããã¯çŽ0ïŒ75%ããçŽ5%ã®ç·éã§çµæç©äžã«ååšããã
湿最å€
æ¬çºæã®çµæç©ã¯ãææã«ããïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã湿最å€ãå«ããçé¢æŽ»æ§å€ã芪氎æ§ããªããŒããã³ç¹å®ã®ç²åã¯ãæµåå±€é ç²æ³äžã«ããã«ãã³ãã·ããªã©ã®çæ°Žæ§è¬å€ã®æ¹¿æœ€ãå©ãã湿最å€ãšããŠå Žåã«ããæçšã§ããã
çå³å€
æ¬çºæã®çµæç©ã¯ãïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ãããçå³å€(æ¬æ现æžã§ã¯çå³æãšã
称ãã)ãå«ããå€ãã®å»è¬å賊圢å€ã¯çå³ãæããäºãç解ãããããæ¬æ现æžã«ãã
ãŠã"çå³å€"ãŸãã¯"çå³æ"ãšããçšèªã¯ãéç³è³ªããã³éç³ã¢ã«ã³ãŒã«çå³æã®ããšãèšãããããçå³æã®ééå®çãªäŸã¯ãã¢ã»ã¹ã«ãã¡ã Kãã¢ã¹ãã«ããŒã ããã«ãããŒ
ã«ãããªããŒã ããµãã«ãªã³ããµãã«ãªã³ãããªãŠã ããµã€ã¯ã©ãã³é žãããªãŠã ãããã³ãããã®å¡©ãå«ãã奜ãŸããã¯ãæ¬çºæã®çµæç©äžã«ãçå³æã¯ãçµæç©ééã®0ïŒ05%
ããçŽ10%ã奜ãŸããã¯çŽ0ïŒ5ããçŽ7ïŒ5%ããããŠããã«å¥œãŸããã¯çŽ0ïŒ75%ããçŽ5%ã®ç·éã§çµæç©äžã«ååšããã
湿最å€
æ¬çºæã®çµæç©ã¯ãææã«ããïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã湿最å€ãå«ããçé¢æŽ»æ§å€ã芪氎æ§ããªããŒããã³ç¹å®ã®ç²åã¯ãæµåå±€é ç²æ³äžã«ããã«ãã³ãã·ããªã©ã®çæ°Žæ§è¬å€ã®æ¹¿æœ€ãå©ãã湿最å€ãšããŠå Žåã«ããæçšã§ããã
æ¬çºæã®çµæç©ã«ããã湿最å€ãšããŠçšããããšãã§ããçé¢æŽ»æ§å€ã®ééå®çãªäŸã¯ãåçŽã¢ã³ã¢ããŠã ååç©(äŸãã°ãå¡©åãã³ã¶ã«ã³ããŠã ãå¡©åãã³ãŒãããŠã ããã³
å¡©åã»ãã«ããªãžããŠã )ãã¹ã«ãã³ãã¯é žãžãªã¯ãã«ãããªãŠã ãããªãªãã·ãšãã¬ã³
ã¢ã«ãã«ãã§ãã«ãšãŒãã«(äŸãã°ããããã·ããŒã«9ããããã·ããŒã«10ïŒããã³ãªã¯ããã·ããŒã«9ïŒãããããµããŒ(ããªãªãã·ãšãã¬ã³ããã³ããªãªãã·ãããã¬ã³ãããã¯ã³ããªããŒ)ãããªãªãã·ãšãã¬ã³èèªé žã°ãªã»ãªãããã³ãªã€ã«(äŸãã°ãããªãªãã·ãšãã¬ã³(8)ã«ããªã«é ž/ã«ããªã³é žã¢ã-ããã³ãžã°ãªã»ãªã(äŸãã°ãGattefosseã®ã©ãã©ãŸãŒã«(ç»é²åæš))ãããªãªãã·ãšãã¬ã³(35)ã²ãŸãæ²¹ããã³ããªãªãã·ãšãã¬ã³(40)æ°Ž
æ·»ã²ãŸãæ²¹ïŒããªãªãã·ãšãã¬ã³ã¢ã«ãã«ãšãŒãã«(äŸãã°ãããªãªãã·ãšãã¬ã³(20)ã»
ãã¹ãã¢ãªã«ãšãŒãã«ãããªãªãã·ãšãã¬ã³èèªé žãšã¹ãã«(äŸãã°ã¹ãã¢ãªã³é žããªãª
ãã·ãšãã¬ã³(40))ãããªãªãã·ãšãã¬ã³ãœã«ãã¿ã³ãšã¹ãã«(äŸãã°ããªãœã«ããŒã20ããã³ããªãœã«ããŒã80(äŸãã°ICIã®ãã€ãŒã³(ç»é²åæš)80))ããããã¬ã³ã°ãªã³ãŒã«èèªé žãšã¹ãã«(äŸãã°ã©ãŠãªã«é žãããã¬ã³ã°ãªã³ãŒã«(äŸãã°ãGattefosseã®ã©ãŠãã°ãªã³ãŒã«))ãã©ãŠãªã«ç¡«é žãããªãŠã ãèèªé žããã³ãã®å¡©(äŸãã°ãªã¬ã€ã³é žããªã¬ã€ã³é ž
ãããªãŠã ããã³ãªã¬ã€ã³é žããªãšã¿ããŒã«ã¢ãã³ãã°ãªã»ãªã³èèªé žãšã¹ãã«(äŸãã°
ã¢ãã¹ãã¢ãªã³é žã°ãªã»ãªã«)ããœã«ãã¿ã³ãšã¹ãã«(äŸãã°ã¢ãã©ãŠãªã«é žãœã«ãã¿ã³ãã¢ããªã¬ã€ã³é žãœã«ãã¿ã³ãã¢ããã«ããã³é žãœã«ãã¿ã³ãããã³ã¢ãã¹ãã¢ãªã³é žãœã«ãã¿ã³)ãããããµããŒã«ãããã³ãããã®æ··åç©ãå«ããã©ãŠãªã«ç¡«é žãããªãŠã ã¯ã
æ¬çºæã®çµæç©ã«ããã奜ãŸãã湿最å€ã§ããã
å¡©åã»ãã«ããªãžããŠã )ãã¹ã«ãã³ãã¯é žãžãªã¯ãã«ãããªãŠã ãããªãªãã·ãšãã¬ã³
ã¢ã«ãã«ãã§ãã«ãšãŒãã«(äŸãã°ããããã·ããŒã«9ããããã·ããŒã«10ïŒããã³ãªã¯ããã·ããŒã«9ïŒãããããµããŒ(ããªãªãã·ãšãã¬ã³ããã³ããªãªãã·ãããã¬ã³ãããã¯ã³ããªããŒ)ãããªãªãã·ãšãã¬ã³èèªé žã°ãªã»ãªãããã³ãªã€ã«(äŸãã°ãããªãªãã·ãšãã¬ã³(8)ã«ããªã«é ž/ã«ããªã³é žã¢ã-ããã³ãžã°ãªã»ãªã(äŸãã°ãGattefosseã®ã©ãã©ãŸãŒã«(ç»é²åæš))ãããªãªãã·ãšãã¬ã³(35)ã²ãŸãæ²¹ããã³ããªãªãã·ãšãã¬ã³(40)æ°Ž
æ·»ã²ãŸãæ²¹ïŒããªãªãã·ãšãã¬ã³ã¢ã«ãã«ãšãŒãã«(äŸãã°ãããªãªãã·ãšãã¬ã³(20)ã»
ãã¹ãã¢ãªã«ãšãŒãã«ãããªãªãã·ãšãã¬ã³èèªé žãšã¹ãã«(äŸãã°ã¹ãã¢ãªã³é žããªãª
ãã·ãšãã¬ã³(40))ãããªãªãã·ãšãã¬ã³ãœã«ãã¿ã³ãšã¹ãã«(äŸãã°ããªãœã«ããŒã20ããã³ããªãœã«ããŒã80(äŸãã°ICIã®ãã€ãŒã³(ç»é²åæš)80))ããããã¬ã³ã°ãªã³ãŒã«èèªé žãšã¹ãã«(äŸãã°ã©ãŠãªã«é žãããã¬ã³ã°ãªã³ãŒã«(äŸãã°ãGattefosseã®ã©ãŠãã°ãªã³ãŒã«))ãã©ãŠãªã«ç¡«é žãããªãŠã ãèèªé žããã³ãã®å¡©(äŸãã°ãªã¬ã€ã³é žããªã¬ã€ã³é ž
ãããªãŠã ããã³ãªã¬ã€ã³é žããªãšã¿ããŒã«ã¢ãã³ãã°ãªã»ãªã³èèªé žãšã¹ãã«(äŸãã°
ã¢ãã¹ãã¢ãªã³é žã°ãªã»ãªã«)ããœã«ãã¿ã³ãšã¹ãã«(äŸãã°ã¢ãã©ãŠãªã«é žãœã«ãã¿ã³ãã¢ããªã¬ã€ã³é žãœã«ãã¿ã³ãã¢ããã«ããã³é žãœã«ãã¿ã³ãããã³ã¢ãã¹ãã¢ãªã³é žãœã«ãã¿ã³)ãããããµããŒã«ãããã³ãããã®æ··åç©ãå«ããã©ãŠãªã«ç¡«é žãããªãŠã ã¯ã
æ¬çºæã®çµæç©ã«ããã奜ãŸãã湿最å€ã§ããã
ïŒçš®é¡ä»¥äžã®æ¹¿æœ€å€ã¯ãææã«ãããäžè¬çã«ãçµæç©ééã®çŽ0ïŒ05%ããçŽ5%ã奜ãŸããã¯çŽ0ïŒ075%ããçŽ2ïŒ5%ããããŠããã«å¥œãŸããã¯çŽ0ïŒ25%ããçŽ1%ãäŸãã°çŽ0ïŒ5%ã®ç·éã§ãæ¬çºæã®çµæç©äžã«ååšããã
é氎溶æ§æ»æ²¢å€
æ¬çºæã®çµæç©ã¯ãææã«ãããæ äœææãšããŠïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ãããé氎溶æ§æ»æ²¢å€ãå«ããé©åãªé氎溶æ§æ»æ²¢å€ã¯ãåç¬ãããã¯çµã¿åããã®ããããã§ãããã³é žã°ãªã»ãªã«(äŸãã°ã³ã³ããªããŒã«(ç»é²åæš)888)ãã¹ãã¢ãªã³é žå¡©(ãã°ãã·ãŠã ãã«ã«ã·ãŠã ïŒããã³ãããªãŠã )ãã¹ãã¢ãªã³é žã硬åæ€ç©æ²¹(äŸãã°ãã¹ããããã¯ã¹(ç»é²åæš))ãã³ãã€ãã«ã·ãªã«ãã¿ã«ã¯ãããããã³ãããã®æ··åç©ãå«ããææã«ã
ããé氎溶æ§æ»æ²¢å€ã¯ã湿最å€ãšæ··åããŠçšããããšãã§ããäŸãã°ãã¹ãã¢ãªã³é žã«ã«ã·ãŠã /ã©ãŠãªã«ç¡«é žãããªãŠã æ··åç©(äŸãã°ã¹ãããŠãšãã(Sterowet,ç»é²åæš))ã§çšããäºãã§ããã
é氎溶æ§æ»æ²¢å€
æ¬çºæã®çµæç©ã¯ãææã«ãããæ äœææãšããŠïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ãããé氎溶æ§æ»æ²¢å€ãå«ããé©åãªé氎溶æ§æ»æ²¢å€ã¯ãåç¬ãããã¯çµã¿åããã®ããããã§ãããã³é žã°ãªã»ãªã«(äŸãã°ã³ã³ããªããŒã«(ç»é²åæš)888)ãã¹ãã¢ãªã³é žå¡©(ãã°ãã·ãŠã ãã«ã«ã·ãŠã ïŒããã³ãããªãŠã )ãã¹ãã¢ãªã³é žã硬åæ€ç©æ²¹(äŸãã°ãã¹ããããã¯ã¹(ç»é²åæš))ãã³ãã€ãã«ã·ãªã«ãã¿ã«ã¯ãããããã³ãããã®æ··åç©ãå«ããææã«ã
ããé氎溶æ§æ»æ²¢å€ã¯ã湿最å€ãšæ··åããŠçšããããšãã§ããäŸãã°ãã¹ãã¢ãªã³é žã«ã«ã·ãŠã /ã©ãŠãªã«ç¡«é žãããªãŠã æ··åç©(äŸãã°ã¹ãããŠãšãã(Sterowet,ç»é²åæš))ã§çšããäºãã§ããã
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã ïŒã¹ãã¢ãªã³é
žããã³ãã®æ··åç©ã¯ã奜ãŸããé氎溶æ§æ»æ²¢å€ã§ããã
æ¬çºæã®çµæç©äžã«ãããïŒçš®é¡ä»¥äžã®é氎溶æ§æ»æ²¢å€ã¯ãçµæç©ééã®çŽ0ïŒ05%ããçŽ5%ã奜ãŸããã¯çŽ0ïŒ75%ããçŽ2ïŒ5%ïŒãããŠããã«å¥œãŸããã¯çŽ1%ããçŽ2%ãäŸãã°
çŽ1ïŒ5%ã®å žåçãªç·éã§ãææã«ããååšããã
氎溶æ§æ»æ²¢å€
æ¬çºæã®çµæç©ã¯ãææã«ããã1çš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã氎溶æ§æ»æ²¢å€ãå«ã
ã氎溶æ§æ»æ²¢å€ã¯ãé å€ã®æ°Žæº¶æ§ãæ¹åããã®ã«æçšã§ãããåç¬ã§ããããã¯çµã¿åããã®ããããã§æ¬çºæã®çµæç©ã«çšããããšã®ã§ãã氎溶æ§æ»æ²¢å€ã¯ãäŸãã°ãããŠé žãå®æ¯éŠé žãããªãŠã ãé ¢é žãããªãŠã ãããã«é žãããªãŠã ãå¡©åãããªãŠã ãDL-ãã€
ã·ã³ãããªãšãã¬ã³ã°ãªã³ãŒã«(äŸãã°ãã«ãŒãã¯ãã¯ã¹(ç»é²åæš)4000ããã³ã«ãŒãã¯
ãã¯ã¹6000ïŒãããã³ãªã¬ã€ã³é žãããªãŠã ãå«ãã
厩å£å€
æ¬çºæã®çµæç©ã¯ãææã«ããïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã厩å£å€ãå«ããããããªãããæ¬æ现æžã«èšèŒã®å£è å é溶é ã¯ãäžè¬çã«å£è å ã§æ¥éã«åŽ©å£ãã厩å£å€ã®æ·»å ãå¿ èŠãšããªããææã§ããã°ãé©åãªåŽ©å£å€ã¯ãåç¬ãŸãã¯çµã¿åããã§ããã³ãã³ããã³ãã³ã°ãªã³ãŒã«é žãããªãŠã ãç²åïŒããŒã¬ã (ç»é²åæšïŒHVãªã©ïŒãã»ã«ããŒã¹
é¡ïŒäŸãã°ç²Ÿè£œã»ã«ããŒã¹ãã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãããªãŠã ããã³ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãªã©ïŒãã¯ãã¹ã«ã«ã¡ããŒã¹ãããªãŠã ãã¢ã«ã®ã³é žå¡©ãã¢ã«ãã¡åã³ãŒã³ã¹ã¿ãŒãïŒãã·ã§ãã«ïŒNational)(ç»é²åæš)1551ããã³ãã·ã§ã
ã«(National)(ç»é²åæšïŒ1550ãªã©ïŒãã¯ãã¹ãããã³ãããã³å¢ç²å€ïŒå¯å€©ãã°ã¢ãŒã«
ãŽã ãããŒã«ã¹ãããŒã³ãŽã ãã«ã©ã€ãŽã ããã¯ãã³ããã³ãã©ã¬ã³ããŽã ãªã©ïŒãå«ãã厩å£å€ã¯çµæç©ã®äœæäžã®ãããã®é©åãªã¹ãããã«ãããŠãæ·»å ããããšãã§ãããããšãããæµåå±€é ç²ã®åãããã¯æäžã«æ·»å ããããšãã§ãããã¯ãã¹ã«ã«ã¡ããŒã¹ãããªãŠã ããã³ãã³ãã³ã°ãªã³ãŒã«é žãããªãŠã ã¯å¥œãŸãã厩å£å€ã§ããã
æ¬çºæã®çµæç©äžã«ãããïŒçš®é¡ä»¥äžã®é氎溶æ§æ»æ²¢å€ã¯ãçµæç©ééã®çŽ0ïŒ05%ããçŽ5%ã奜ãŸããã¯çŽ0ïŒ75%ããçŽ2ïŒ5%ïŒãããŠããã«å¥œãŸããã¯çŽ1%ããçŽ2%ãäŸãã°
çŽ1ïŒ5%ã®å žåçãªç·éã§ãææã«ããååšããã
氎溶æ§æ»æ²¢å€
æ¬çºæã®çµæç©ã¯ãææã«ããã1çš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã氎溶æ§æ»æ²¢å€ãå«ã
ã氎溶æ§æ»æ²¢å€ã¯ãé å€ã®æ°Žæº¶æ§ãæ¹åããã®ã«æçšã§ãããåç¬ã§ããããã¯çµã¿åããã®ããããã§æ¬çºæã®çµæç©ã«çšããããšã®ã§ãã氎溶æ§æ»æ²¢å€ã¯ãäŸãã°ãããŠé žãå®æ¯éŠé žãããªãŠã ãé ¢é žãããªãŠã ãããã«é žãããªãŠã ãå¡©åãããªãŠã ãDL-ãã€
ã·ã³ãããªãšãã¬ã³ã°ãªã³ãŒã«(äŸãã°ãã«ãŒãã¯ãã¯ã¹(ç»é²åæš)4000ããã³ã«ãŒãã¯
ãã¯ã¹6000ïŒãããã³ãªã¬ã€ã³é žãããªãŠã ãå«ãã
厩å£å€
æ¬çºæã®çµæç©ã¯ãææã«ããïŒçš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã厩å£å€ãå«ããããããªãããæ¬æ现æžã«èšèŒã®å£è å é溶é ã¯ãäžè¬çã«å£è å ã§æ¥éã«åŽ©å£ãã厩å£å€ã®æ·»å ãå¿ èŠãšããªããææã§ããã°ãé©åãªåŽ©å£å€ã¯ãåç¬ãŸãã¯çµã¿åããã§ããã³ãã³ããã³ãã³ã°ãªã³ãŒã«é žãããªãŠã ãç²åïŒããŒã¬ã (ç»é²åæšïŒHVãªã©ïŒãã»ã«ããŒã¹
é¡ïŒäŸãã°ç²Ÿè£œã»ã«ããŒã¹ãã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãããªãŠã ããã³ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãªã©ïŒãã¯ãã¹ã«ã«ã¡ããŒã¹ãããªãŠã ãã¢ã«ã®ã³é žå¡©ãã¢ã«ãã¡åã³ãŒã³ã¹ã¿ãŒãïŒãã·ã§ãã«ïŒNational)(ç»é²åæš)1551ããã³ãã·ã§ã
ã«(National)(ç»é²åæšïŒ1550ãªã©ïŒãã¯ãã¹ãããã³ãããã³å¢ç²å€ïŒå¯å€©ãã°ã¢ãŒã«
ãŽã ãããŒã«ã¹ãããŒã³ãŽã ãã«ã©ã€ãŽã ããã¯ãã³ããã³ãã©ã¬ã³ããŽã ãªã©ïŒãå«ãã厩å£å€ã¯çµæç©ã®äœæäžã®ãããã®é©åãªã¹ãããã«ãããŠãæ·»å ããããšãã§ãããããšãããæµåå±€é ç²ã®åãããã¯æäžã«æ·»å ããããšãã§ãããã¯ãã¹ã«ã«ã¡ããŒã¹ãããªãŠã ããã³ãã³ãã³ã°ãªã³ãŒã«é žãããªãŠã ã¯å¥œãŸãã厩å£å€ã§ããã
çµæç©ééã®çŽ0ïŒ05%ããçŽ15%ã奜ãŸããã¯0ïŒ5%ããçŽ10%ããããŠããã«å¥œãŸãã
ã¯çŽ1%ããçŽ3ïŒ5%ã®ç·éã§ã1çš®é¡ä»¥äžã®åŽ©å£å€ãææã«ããååšããã
æµåä¿é²å€
æ¬çºæã®çµæç©ã¯ææã«ãããäŸãã°é å€éåãžã®æé çšåæã®æµåæ§ãé«ãããããæé çšåæã®ãã³ããŸãã¯éåãžã®åºçãé²ãããïŒãããã¯å æ²¢ãæããé å€ã補é ããããã®ã1çš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ãããæµåä¿é²å€ãå«ããæµåä¿é²å€ã¯ãçµæç©ã®
補é äžããããã®é©åãªã¹ãããã«ãããŠãå ããããšãã§ãããããšãããé ç²ã®åã«ããããã¯é å€å§çž®ã®åã®æ··åã¹ãããäžã«å ããããšãã§ããã
ã¯çŽ1%ããçŽ3ïŒ5%ã®ç·éã§ã1çš®é¡ä»¥äžã®åŽ©å£å€ãææã«ããååšããã
æµåä¿é²å€
æ¬çºæã®çµæç©ã¯ææã«ãããäŸãã°é å€éåãžã®æé çšåæã®æµåæ§ãé«ãããããæé çšåæã®ãã³ããŸãã¯éåãžã®åºçãé²ãããïŒãããã¯å æ²¢ãæããé å€ã補é ããããã®ã1çš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ãããæµåä¿é²å€ãå«ããæµåä¿é²å€ã¯ãçµæç©ã®
補é äžããããã®é©åãªã¹ãããã«ãããŠãå ããããšãã§ãããããšãããé ç²ã®åã«ããããã¯é å€å§çž®ã®åã®æ··åã¹ãããäžã«å ããããšãã§ããã
çè«ã«æããããããã§ã¯ãªãããå Žåã«ãã£ãŠã¯ãäŸãã°ã¿ã«ã¯ãŸãã¯äºé
žåçªçŽ ãªã©ã®æµåä¿é²å€ã¯ãè¬ç©åéãé»å®³ããã³/ãŸãã¯æžå°ãããå¹æãæããè¬ç©ç²åéã®
çé¢åŒµåãæžå°ããããã«äœçšããè¬å€ç²æ«ã®è¡šé¢ã®åž¯é»ãæžå°ããããã«äœçšãããããŠè¬ç©ç²åã®ç²åéæ©æŠããã³è¡šé¢ã®ã§ããŒãæ§ãæžå°ããããã«äœçšãããšèãããããäŸãã°ãYork (1975) J. Pharm. Sci. , 64 (7), 1216-1221 ãåç §ã®äºã
çé¢åŒµåãæžå°ããããã«äœçšããè¬å€ç²æ«ã®è¡šé¢ã®åž¯é»ãæžå°ããããã«äœçšãããããŠè¬ç©ç²åã®ç²åéæ©æŠããã³è¡šé¢ã®ã§ããŒãæ§ãæžå°ããããã«äœçšãããšèãããããäŸãã°ãYork (1975) J. Pharm. Sci. , 64 (7), 1216-1221 ãåç §ã®äºã
äºé
žåçªçŽ ã¯ã奜ãŸããæµåä¿é²å€ã§ãããæ¬çºæã®çµæç©ã®è£œé ã«ããã䜿çšã®ããã®é©åãªäºé
žåçªçŽ 補åã¯ã也åŒã·ãªã«ãŸãã¯ã³ãã€ãã«ã·ãªã«ïŒäŸãã°ããã£ãããã®Cab-O-Sil(ç»é²åæš)ããã³ãã°ãµã®ãšã¢ããžã«(ç»é²åæš))ãå«ããæ¬çºæã®çµæç©ã«çšããå Žåãäºé
žåçªçŽ ã¯ãçµæç©ã®ééã®çŽ0ïŒ05%ããçŽ5%ã奜ãŸããã¯çŽ0ïŒ1%ããçŽ2%ããããŠããã«å¥œãŸããã¯çŽ0ïŒ25%ããçŽ1%ãäŸãã°ãçŽ0ïŒ5%ã®ç·éã§ååšããã
颚å³å€
æ¬çºæã®çµæç©ã¯ãææã«ãã1çš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã颚å³å€ãå«ããæ¬çºæ
ã®çµæç©ã«çšããããšãã§ãã颚å³å€ã®ééå®çãªäŸã¯ããããŒãã³ããã¹ãã¢ãã³ãããããŠããµã¯ã©ã³ããã€ããŽãã¬ã¢ã³ããªã¬ã³ãžãªã©ãå«ãã
é å€ã®ç¹åŸŽ
倧ãããšåœ¢
奜ãŸããå®æœæ æ§ã«ãããŠãæ¬çºæã®çµæç©ã¯ãåé¢ããåºäœã®åäœè£œå€ã§ãããæã奜ãŸããã¯é å€ã®åœ¢ã§ãããæ¬çºæã®é å€ã¯ææã®å€§ãããäŸãã°ã8mmã10mmã12mmã
ãªã©ïŒåœ¢ãäŸãã°å圢ãæ¥å圢ãé·æ¹åœ¢ãªã©ïŒééïŒããã³åãã®ãããã«ã補é ããããšãã§ãããææã«ãããæ¬çºæã®åäœã®åäœè£œå€ã¯ããšããã³ã°ãŸãã¯ã¢ãã°ã©ã ãçæ¹ãŸãã¯äž¡æ¹ã«æããããšãã§ããã
厩å£
æ¬çºæã®å¥œãŸããé å€çµæç©ã¯ãæšæºçãªin vitro 厩å£è©Šéšã«ãããŠ(äŸãã°ãç±³åœè¬å±æ¹24(2000)ãTest No. 701ã«åŸã£ãŠ)ã300ç§æªæºã«ã奜ãŸããã¯ãçŽ200ç§æªæºã«ãã
ããŠããã«å¥œãŸããã¯çŽ100ç§æªæºã«ãäŸãã°çŽ30ç§æªæºã«åŽ©å£ããã
颚å³å€
æ¬çºæã®çµæç©ã¯ãææã«ãã1çš®é¡ä»¥äžã®è¬åŠçã«èš±å®¹ããã颚å³å€ãå«ããæ¬çºæ
ã®çµæç©ã«çšããããšãã§ãã颚å³å€ã®ééå®çãªäŸã¯ããããŒãã³ããã¹ãã¢ãã³ãããããŠããµã¯ã©ã³ããã€ããŽãã¬ã¢ã³ããªã¬ã³ãžãªã©ãå«ãã
é å€ã®ç¹åŸŽ
倧ãããšåœ¢
奜ãŸããå®æœæ æ§ã«ãããŠãæ¬çºæã®çµæç©ã¯ãåé¢ããåºäœã®åäœè£œå€ã§ãããæã奜ãŸããã¯é å€ã®åœ¢ã§ãããæ¬çºæã®é å€ã¯ææã®å€§ãããäŸãã°ã8mmã10mmã12mmã
ãªã©ïŒåœ¢ãäŸãã°å圢ãæ¥å圢ãé·æ¹åœ¢ãªã©ïŒééïŒããã³åãã®ãããã«ã補é ããããšãã§ãããææã«ãããæ¬çºæã®åäœã®åäœè£œå€ã¯ããšããã³ã°ãŸãã¯ã¢ãã°ã©ã ãçæ¹ãŸãã¯äž¡æ¹ã«æããããšãã§ããã
厩å£
æ¬çºæã®å¥œãŸããé å€çµæç©ã¯ãæšæºçãªin vitro 厩å£è©Šéšã«ãããŠ(äŸãã°ãç±³åœè¬å±æ¹24(2000)ãTest No. 701ã«åŸã£ãŠ)ã300ç§æªæºã«ã奜ãŸããã¯ãçŽ200ç§æªæºã«ãã
ããŠããã«å¥œãŸããã¯çŽ100ç§æªæºã«ãäŸãã°çŽ30ç§æªæºã«åŽ©å£ããã
ãããã¯ããŸãã¯ããã«ãæ¬çºæã®å¥œãŸããé溶çµæç©ã¯ã被éšè
ã®å£è
å
ã«ãããŠãçŽ60ç§ä»¥å
ã«ã奜ãŸããã¯çŽ30ç§ä»¥å
ã«ããããŠããã«å¥œãŸããã¯çŽ15ç§ä»¥å
ã«åŽ©å£ããã
硬床
æ¬çºæã®åºåœ¢å€ã¯ãç¹åŸŽã®äžã§ãšããããçµæãšå ±ã«å€§ãããšåœ¢ã«äŸåããå¯èœæ§ããã硬床ãæãããé å€ç¡¬åºŠã¯ãåœè©²æè¡åéã«å ¬ç¥ã®ãããã®æ¹æ³ã«ãã£ãŠã枬å®ããããšãã§ããããäŸãã°ãé å€ç¡¬åºŠèš(äŸãã°ãã·ã¥ããã¬ãŒè£œ)ã«ãã枬å®ã§ããã奜ãŸããã¯ãæ¬çºæã®è£œå€ã¯ãçŽ1ãã10kpããããŠããã«å¥œãŸããã¯çŽ1ããçŽ6kpã®ç¡¬åºŠãæ
ããã
硬床
æ¬çºæã®åºåœ¢å€ã¯ãç¹åŸŽã®äžã§ãšããããçµæãšå ±ã«å€§ãããšåœ¢ã«äŸåããå¯èœæ§ããã硬床ãæãããé å€ç¡¬åºŠã¯ãåœè©²æè¡åéã«å ¬ç¥ã®ãããã®æ¹æ³ã«ãã£ãŠã枬å®ããããšãã§ããããäŸãã°ãé å€ç¡¬åºŠèš(äŸãã°ãã·ã¥ããã¬ãŒè£œ)ã«ãã枬å®ã§ããã奜ãŸããã¯ãæ¬çºæã®è£œå€ã¯ãçŽ1ãã10kpããããŠããã«å¥œãŸããã¯çŽ1ããçŽ6kpã®ç¡¬åºŠãæ
ããã
çŸåšå¥œãŸããå®æœæ
æ§ã«ãããŠãæ¬çºæã®åºåœ¢å€ã¯ãåãæ±ãã®ããã®ååãªç¡¬åºŠãæããããã«ããéåžžã®é å€ãšåæ§ã«å®çšã«äŸãããããšãã§ãããæ¬æ现æžã«äœ¿çšãããŠãã"åãæ±ãã®ããã®ååãªç¡¬åºŠ"ãšããçšèªã¯ãå°ãªããšãæšæºã¿ã€ãã®ããªã¹ã¿ãŒããã¯ã®å¥é¢ã«èããããšãã§ãã硬床ããããã¯å
è£
ãé
éãæºè¡ãªã©ã®ä»ã®åãæ±ãã«èãã硬床ãæå³ããã
æ¬çºæã®é å€ã¯ã奜ãŸããã¯ãã«ããŒã·ãŒããéããŠé å€ãæŒãããšã«ãããæšæºçãªããªã¹ã¿ãŒããã¯ããã®å¥é¢ã®éã«é å€ã®ç Žæã«èããããã®æå°éã®ç¡¬åºŠãæãããé©åãªç¡¬åºŠã¯ãçŽ8mmã®çŽåŸãæããé å€ã«é¢ããŠçŽ1kp以äžã§ãããçŽ10mmã®çŽåŸãæããé å€ã«é¢ããŠçŽ1ïŒ5kpã§ããããããŠçŽ12mmã®çŽåŸãæããé å€ã®å ŽåãçŽ2kp以äžã§ã
ãã
ãã
ãã1ã€ã®ãçŸåšå¥œãŸããå®æœæ
æ§ã«ãããŠãæ¬çºæã®é å€ã¯ãåå¥ã«å
è£
ããã®ã§ã¯
ãªããäŸãã°ã¬ã©ã¹ãŸãã¯ãã©ã¹ãã£ãã¯ããã«ã«ãããé å€ãè€æ°å è£ ããããšããéåžžã®åºè·ããã³åãæ±ãã®éãå®è³ªçãªç ŽæãŸãã¯åºçããã³/ãŸãã¯èåã瀺ãããšãª
ãã§ããããããå è£ ãç®çãšããé å€ã¯ã奜ãŸããã¯ãçŽ3kp以äžã®ç¡¬åºŠãæããã
å è£
æ¬çºæã®çµæç©ã¯ãåœè©²æè¡åéã«å ¬ç¥ã®ãããã®é©åãªæ¹æ³ãçšããŠãå è£ ã§ãããäŸãã°ãè€æ°ã®é溶é ããã¬ã©ã¹ãŸãã¯ãã©ã¹ãã£ãã¯ã®ããã«ãããã¯å®¹åšãªã©ã«äžç·ã«å è£ ããããšãã§ããããããã¯ãæ¬çºæã®é溶é ãããã©ã¹ãã£ãã¯ãŸãã¯ãã€ã«äžã«åå¥ã«å ããããããã¯åšç¥ã®åœ¢ã®ããªã¹ã¿ãŒããã¯ã«å è£ ããããšãã§ãããGrabowskiãžã®ç±³åœç¹èš±ç¬¬5ïŒ954ïŒ204å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«é瀺ãããŠãããããªåé åç¹æ§ã®æ¹åã䌎ãããªã¹ã¿ãŒããã¯ã¯ãæ¬çºæã®é溶é ãå è£ ããã®ã«ãšãããæçšã§ããã
é溶é ã®æäž
æ¬çºæã®çµæç©ã¯ã被éšè ã®éžæãŸãã¯çç¶ã«åºã¥ãããããã®çµå£æäžæ³ã«ãã£ãŠã被éšè ã«æäžããããšãã§ãããäŸãã°ãæ¬çºæã®é溶é ã¯ãæ°Žãçšããã«æåããããšãã§ãããå£è å ã«å ¥ããããšã«ããããããŠãšããããã»ã»ãããã¯èäžã§ããããé å€ã¯åŸæ¶²ã«ãããããæ¥éã«åŽ©å£ããŠãã®äžã«æº¶è§£ããã厩å£é床ããã³/ãŸãã¯æº¶è§£é
床ã¯ãäŸãã°å£èããã³èã®éã®å§åããããã¯ãªãå§åãããã¯åžåŒå§åãªã©ã®å£è å å§åãé å€ã«å ãã£ãå Žåãããã«å¢å ããã
ãªããäŸãã°ã¬ã©ã¹ãŸãã¯ãã©ã¹ãã£ãã¯ããã«ã«ãããé å€ãè€æ°å è£ ããããšããéåžžã®åºè·ããã³åãæ±ãã®éãå®è³ªçãªç ŽæãŸãã¯åºçããã³/ãŸãã¯èåã瀺ãããšãª
ãã§ããããããå è£ ãç®çãšããé å€ã¯ã奜ãŸããã¯ãçŽ3kp以äžã®ç¡¬åºŠãæããã
å è£
æ¬çºæã®çµæç©ã¯ãåœè©²æè¡åéã«å ¬ç¥ã®ãããã®é©åãªæ¹æ³ãçšããŠãå è£ ã§ãããäŸãã°ãè€æ°ã®é溶é ããã¬ã©ã¹ãŸãã¯ãã©ã¹ãã£ãã¯ã®ããã«ãããã¯å®¹åšãªã©ã«äžç·ã«å è£ ããããšãã§ããããããã¯ãæ¬çºæã®é溶é ãããã©ã¹ãã£ãã¯ãŸãã¯ãã€ã«äžã«åå¥ã«å ããããããã¯åšç¥ã®åœ¢ã®ããªã¹ã¿ãŒããã¯ã«å è£ ããããšãã§ãããGrabowskiãžã®ç±³åœç¹èš±ç¬¬5ïŒ954ïŒ204å·(æ¬é¡ã«åŒçšããŠæŽçšãã)ã«é瀺ãããŠãããããªåé åç¹æ§ã®æ¹åã䌎ãããªã¹ã¿ãŒããã¯ã¯ãæ¬çºæã®é溶é ãå è£ ããã®ã«ãšãããæçšã§ããã
é溶é ã®æäž
æ¬çºæã®çµæç©ã¯ã被éšè ã®éžæãŸãã¯çç¶ã«åºã¥ãããããã®çµå£æäžæ³ã«ãã£ãŠã被éšè ã«æäžããããšãã§ãããäŸãã°ãæ¬çºæã®é溶é ã¯ãæ°Žãçšããã«æåããããšãã§ãããå£è å ã«å ¥ããããšã«ããããããŠãšããããã»ã»ãããã¯èäžã§ããããé å€ã¯åŸæ¶²ã«ãããããæ¥éã«åŽ©å£ããŠãã®äžã«æº¶è§£ããã厩å£é床ããã³/ãŸãã¯æº¶è§£é
床ã¯ãäŸãã°å£èããã³èã®éã®å§åããããã¯ãªãå§åãããã¯åžåŒå§åãªã©ã®å£è å å§åãé å€ã«å ãã£ãå Žåãããã«å¢å ããã
ãããã¯ãæ¬çºæã®é å€ã¯ãå£è
å
ã最ããé å€ã®åŽ©å£ãå©ããã®ã«ååãªéã®æ°Žã®å©ããåããŠæåããããšãã§ããããŸããæ¬çºæã®é å€ã¯ãå£è
å
ã§å®å
šã«ãããã¯éšåçã«åŽ©å£ããåŸãå°éã®æ°Žãšå
±ã«é£²ã¿èŸŒãããšãã§ãããæ¬çºæã®çµæç©ã¯ãŸããçŽæ¥ã«æ°Žãšå
±ã«é£²ã¿èŸŒãããšãã§ããã
é溶é ã®è£œé æ¹æ³
以äžã«èšèŒããæ¹æ³ã¯ãæ¬çºæã®ãã«ãã³ãã·ãé溶é ã補é ããããã®ãééå®çãª
ãäŸç€ºã®ããã®æµåå±€é ç²æ³ã§ãããéèŠãªããšã«ã¯ã補é æ¹æ³ã®ç¹å®ã®èšå®ãšãã©ã¡ãŒã¿ãŒã¯ããšãããæãŸããæ§è³ªãæããé å€ã補é ããããã«åœæ¥è ã«ãã容æã«æé©åã§ããããšã§ããã
é溶é ã®è£œé æ¹æ³
以äžã«èšèŒããæ¹æ³ã¯ãæ¬çºæã®ãã«ãã³ãã·ãé溶é ã補é ããããã®ãééå®çãª
ãäŸç€ºã®ããã®æµåå±€é ç²æ³ã§ãããéèŠãªããšã«ã¯ã補é æ¹æ³ã®ç¹å®ã®èšå®ãšãã©ã¡ãŒã¿ãŒã¯ããšãããæãŸããæ§è³ªãæããé å€ã補é ããããã«åœæ¥è ã«ãã容æã«æé©åã§ããããšã§ããã
ãã®äŸç€ºã®ããã®æ¹æ³ã«ãããŠãæ¥éãªå£è
å
溶解ã瀺ãå°ãªããšãïŒã€ã®è³Šåœ¢å€ãçå³å€ããã³ææã«ãã湿最å€ããã³/ãŸãã¯åŽ©å£å€ãã容åšäžã®æ°Žã«æº¶è§£(60âã§)ããŠã¹
ãã¬ãŒæ¶²ãäœæãããææã«ããæµåä¿é²å€(äŸãã°ã³ãã€ãç¶äºé žåçªçŽ ïŒãšå ±ã«çšã
ãŠã埮ç²åç¶ãã«ãã³ãã·ãã補ç²ããè¬å€ç²æ«ãäœæãããã¹ãã¬ãŒæ¶²ãçšããŠãè¬å€ç²æ«ãæµåå±€é ç²ããåæé çšæ··åç©ãäœæãããã€ãã§ææã«ãããåæé çšæ··åç©ãäŸãã°é¢šå³å€ãçå³æã厩å£å€ããã³æ»æ²¢å€ãªã©ã®ä»»æã®ææã®å»è¬å賊圢å€ãšæ··åããæé çšæ··åç©ãäœæããã次ã«æé çšæ··åç©ãå転åŒé å€æ©ã§å§çž®ããŠç®çã®é å€ééãšç¡¬åºŠãåŸããã€ãã§åŸãããé å€ãã湿床å¶åŸ¡ãã£ã³ããŒäžã§ãäŸãã°ç©ºæ°æµåŠçãªã©ãé å€ç¡¬åºŠå¢å ã®å¹æãæããåŠçãåããããã
é å€å§çž®
å§çž®ã¯ãåè¿°ã®ããã«è£œé ããé©åãªéã®é¡ç²ã®æé çšæ··åç©ãäžäžã®ãã³ãã®éã§å§çž®ããææãé å€ãªã©ã®åäžåºåœ¢å€ã«åºããå·¥çšã§ãããæ¬çºæã®é溶é ã®è£œé æ³ã«ãããŠãäŸãã°ãåäžãã³ãé å€æ©ãŸãã¯é«éå転åŒé å€æ©ãªã©ãå«ããããã®é©åãªå§çž®æ³ã䜿çšã§ãããæé å§åã¯éå®ããããææã®ç¡¬åºŠãšåŸãããé å€ã®æº¶è§£æ§ã«åŸã£ãŠãé©åãªå§åãéžæããããšãã§ããããã次ã«è¿°ã¹ãæ§ã«ãé å€ãå æž©ããã³å 湿åŠçããå Žåã奜ãŸããã¯çŽ0ïŒ75ããçŽ1ïŒ5kpã®æåã®ç¡¬åºŠ(å æž©ããã³å 湿åŠçã®å)ã«é å€ã
å§çž®ããã
å æž©ããã³å 湿åŠç
ææã«ãããæ¬çºæã®é å€ã¯ãé å€å§çž®å·¥çšã®åŸã«ãå ç±ããã³å 湿åŠçãããããšãã§ããããããåŠçã¯ãäŸãã°ãé å€ç¡¬åºŠãå¢ãããã«å 湿ãã£ã³ããŒäžã§è¡ãããšãã§ãããäŸããããã°ããã®åŠçäžãé å€ãæåã«äŸãã°ãçŽ25âãã32âããã³çŽ80ïŒ ã®çžå¯Ÿæ¹¿åºŠãªã©ã®äœæž©ã§é«æ¹¿åºŠã®ç©ºæ°æµæ¡ä»¶ã§çŽ45åããçŽ120ååŠçãããã€ãã§ãé å€
ããäŸãã°ïŒçŽ35âããçŽ50âãš30ïŒ ã®çžå¯Ÿæ¹¿åºŠãªã©ã®é«æž©äœæ¹¿åºŠæ¡ä»¶ã§çŽ45åãã120
åéåŠçãããçè«ã«æããããããã§ã¯ãªãããé溶é ãäœæž©/é«æ¹¿åºŠãã£ã³ããŒåŠç
ã«ã€ãã§é«æž©/äœæ¹¿åºŠãã£ã³ããŒåŠçãè¡ãããšã«ãããæ¥éãªåŽ©å£ããã³æ¥éãªæº¶è§£ãª
ã©ã®æãŸããé溶æ§ãç ç²ã«ããããšãªããé å€ç¡¬åºŠããã³é å€ç Žç æ§ãå¢ããšèããããã
æ¬çºæã®çµæç©ã®æçšæ§
æ¬çºæã®çµæç©ã¯ãççãçŒçããã³/ãŸãã¯çºç±ãç¹åŸŽãšããé害ãå«ããããã«é
å®ãããªããã·ã¯ããªãã·ã²ããŒãŒïŒ(COX-ïŒ)ã«åªä»ããã倧å€åºãç¯å²ã®é害ã®æ²»çãšäºé²ã«æçšã§ããããããçµæç©ã¯ãšããããCOX-ïŒãè¶ ããCOX-ïŒãžã®éžææ§ãæ¬ ãåŸæ¥ã®éã¹ããã€ãæ§æççè¬(NSAID)ã®çµæç©ãããæ害ãªå¯äœçšãèããå°ãªããšãã
ãããªãå©ç¹ãæãããäŸãã°é¢ç¯çã®æ²»çã«ããããæççå€ãšããŠæçšã§ããããšãããããããçµæç©ã¯ãåŸæ¥ã®NSAIDã®çµæç©ãšæ¯èŒããŠãäžéšæ¶ç®¡æœ°ç圢æããã³åºè¡
ãå«ãæ¶å管æ¯æ§ããã³æ¶å管åºæ¿äœçšã«é¢ããæœåšåã®è»œæžãäœæ¶²è²¯çããã³é«è¡å§ã®å¢æªããããè æ©èœäœäžãªã©ã®è æ§å¯äœçšã«é¢ããæœåšåã®è»œæžãè¡å°æ¿æ©èœã®æå¶ãå«ãåºè¡æéã«é¢ããäœçšã®è»œæžãããã³ããããã¯ã¢ã¹ããªã³åæ¯æ£è ã«ãããåæ¯çºäœã®èªçºã®è»œæžå¹æãæãããåŸã£ãŠãCOX-2éžæçé»å®³å€ãå«ãã§ãªãæ¬çºæã®çµæç©ã¯
ãåŸæ¥ã®NSAIDãçŠå¿ã§ããå ŽåãäŸãã°æ¶åæ§æœ°çãèçãéå±æ§è žçã朰çæ§å€§è žç
ãæ©å®€çãããã¯æ¶å管é害ã®åçºæŽãæããæ£è ã«ãããŠïŒæ¶å管åºè¡ãäœããããã³ãã³è¡çãè¡åç ãŸãã¯ä»ã®åºè¡é害ãªã©ã®è²§è¡çãå«ãååºé害ïŒè çŸæ£ïŒãããã¯è¡åã®æ£è ãŸãã¯æåè¡ç©è³ªãæäžããŠããæ£è ã«ãããŠããããNSAIDã®ä»£æ¿è¬ãšããŠãš
ãããæçšã§ããã
ãã¬ãŒæ¶²ãäœæãããææã«ããæµåä¿é²å€(äŸãã°ã³ãã€ãç¶äºé žåçªçŽ ïŒãšå ±ã«çšã
ãŠã埮ç²åç¶ãã«ãã³ãã·ãã補ç²ããè¬å€ç²æ«ãäœæãããã¹ãã¬ãŒæ¶²ãçšããŠãè¬å€ç²æ«ãæµåå±€é ç²ããåæé çšæ··åç©ãäœæãããã€ãã§ææã«ãããåæé çšæ··åç©ãäŸãã°é¢šå³å€ãçå³æã厩å£å€ããã³æ»æ²¢å€ãªã©ã®ä»»æã®ææã®å»è¬å賊圢å€ãšæ··åããæé çšæ··åç©ãäœæããã次ã«æé çšæ··åç©ãå転åŒé å€æ©ã§å§çž®ããŠç®çã®é å€ééãšç¡¬åºŠãåŸããã€ãã§åŸãããé å€ãã湿床å¶åŸ¡ãã£ã³ããŒäžã§ãäŸãã°ç©ºæ°æµåŠçãªã©ãé å€ç¡¬åºŠå¢å ã®å¹æãæããåŠçãåããããã
é å€å§çž®
å§çž®ã¯ãåè¿°ã®ããã«è£œé ããé©åãªéã®é¡ç²ã®æé çšæ··åç©ãäžäžã®ãã³ãã®éã§å§çž®ããææãé å€ãªã©ã®åäžåºåœ¢å€ã«åºããå·¥çšã§ãããæ¬çºæã®é溶é ã®è£œé æ³ã«ãããŠãäŸãã°ãåäžãã³ãé å€æ©ãŸãã¯é«éå転åŒé å€æ©ãªã©ãå«ããããã®é©åãªå§çž®æ³ã䜿çšã§ãããæé å§åã¯éå®ããããææã®ç¡¬åºŠãšåŸãããé å€ã®æº¶è§£æ§ã«åŸã£ãŠãé©åãªå§åãéžæããããšãã§ããããã次ã«è¿°ã¹ãæ§ã«ãé å€ãå æž©ããã³å 湿åŠçããå Žåã奜ãŸããã¯çŽ0ïŒ75ããçŽ1ïŒ5kpã®æåã®ç¡¬åºŠ(å æž©ããã³å 湿åŠçã®å)ã«é å€ã
å§çž®ããã
å æž©ããã³å 湿åŠç
ææã«ãããæ¬çºæã®é å€ã¯ãé å€å§çž®å·¥çšã®åŸã«ãå ç±ããã³å 湿åŠçãããããšãã§ããããããåŠçã¯ãäŸãã°ãé å€ç¡¬åºŠãå¢ãããã«å 湿ãã£ã³ããŒäžã§è¡ãããšãã§ãããäŸããããã°ããã®åŠçäžãé å€ãæåã«äŸãã°ãçŽ25âãã32âããã³çŽ80ïŒ ã®çžå¯Ÿæ¹¿åºŠãªã©ã®äœæž©ã§é«æ¹¿åºŠã®ç©ºæ°æµæ¡ä»¶ã§çŽ45åããçŽ120ååŠçãããã€ãã§ãé å€
ããäŸãã°ïŒçŽ35âããçŽ50âãš30ïŒ ã®çžå¯Ÿæ¹¿åºŠãªã©ã®é«æž©äœæ¹¿åºŠæ¡ä»¶ã§çŽ45åãã120
åéåŠçãããçè«ã«æããããããã§ã¯ãªãããé溶é ãäœæž©/é«æ¹¿åºŠãã£ã³ããŒåŠç
ã«ã€ãã§é«æž©/äœæ¹¿åºŠãã£ã³ããŒåŠçãè¡ãããšã«ãããæ¥éãªåŽ©å£ããã³æ¥éãªæº¶è§£ãª
ã©ã®æãŸããé溶æ§ãç ç²ã«ããããšãªããé å€ç¡¬åºŠããã³é å€ç Žç æ§ãå¢ããšèããããã
æ¬çºæã®çµæç©ã®æçšæ§
æ¬çºæã®çµæç©ã¯ãççãçŒçããã³/ãŸãã¯çºç±ãç¹åŸŽãšããé害ãå«ããããã«é
å®ãããªããã·ã¯ããªãã·ã²ããŒãŒïŒ(COX-ïŒ)ã«åªä»ããã倧å€åºãç¯å²ã®é害ã®æ²»çãšäºé²ã«æçšã§ããããããçµæç©ã¯ãšããããCOX-ïŒãè¶ ããCOX-ïŒãžã®éžææ§ãæ¬ ãåŸæ¥ã®éã¹ããã€ãæ§æççè¬(NSAID)ã®çµæç©ãããæ害ãªå¯äœçšãèããå°ãªããšãã
ãããªãå©ç¹ãæãããäŸãã°é¢ç¯çã®æ²»çã«ããããæççå€ãšããŠæçšã§ããããšãããããããçµæç©ã¯ãåŸæ¥ã®NSAIDã®çµæç©ãšæ¯èŒããŠãäžéšæ¶ç®¡æœ°ç圢æããã³åºè¡
ãå«ãæ¶å管æ¯æ§ããã³æ¶å管åºæ¿äœçšã«é¢ããæœåšåã®è»œæžãäœæ¶²è²¯çããã³é«è¡å§ã®å¢æªããããè æ©èœäœäžãªã©ã®è æ§å¯äœçšã«é¢ããæœåšåã®è»œæžãè¡å°æ¿æ©èœã®æå¶ãå«ãåºè¡æéã«é¢ããäœçšã®è»œæžãããã³ããããã¯ã¢ã¹ããªã³åæ¯æ£è ã«ãããåæ¯çºäœã®èªçºã®è»œæžå¹æãæãããåŸã£ãŠãCOX-2éžæçé»å®³å€ãå«ãã§ãªãæ¬çºæã®çµæç©ã¯
ãåŸæ¥ã®NSAIDãçŠå¿ã§ããå ŽåãäŸãã°æ¶åæ§æœ°çãèçãéå±æ§è žçã朰çæ§å€§è žç
ãæ©å®€çãããã¯æ¶å管é害ã®åçºæŽãæããæ£è ã«ãããŠïŒæ¶å管åºè¡ãäœããããã³ãã³è¡çãè¡åç ãŸãã¯ä»ã®åºè¡é害ãªã©ã®è²§è¡çãå«ãååºé害ïŒè çŸæ£ïŒãããã¯è¡åã®æ£è ãŸãã¯æåè¡ç©è³ªãæäžããŠããæ£è ã«ãããŠããããNSAIDã®ä»£æ¿è¬ãšããŠãš
ãããæçšã§ããã
ãããçµæç©ã¯ããªãŠããæ§é¢ç¯çãèæ€é¢ç¯çãé颚æ§é¢ç¯çãå€åœ¢æ§é¢ç¯çãå
šèº«æ§ãšãªã¹ãããŒãã¹ãããã³è¥å¹Žæ§é¢ç¯çãééå®çã«å«ãé¢ç¯çŸæ£ã®æ²»çã«æçšã§ãã
ã
ã
ãããçµæç©ã¯ãŸããåæ¯ãæ°ç®¡æ¯ç ãçççãæ©æååš©ãè
±çãæ»æ¶²å
çãã¢ã¬ã«ã®ãŒæ§ç¥çµçããµã€ãã¡ã¬ããŠã€ã«ã¹ææãHIVèªçºã¢ãããŒã·ã¹ãå«ãã¢ãããŒã·
ã¹ãè °çãèçãå«ãèçŸæ£ã也ç¬ã湿ç¹ãã¢ã¯ããç±å·ãç®èçãããã³æ¥çŒããå«ã玫å€ç·ç §å°é害ãªã©ã®ç®èé¢é£çŸæ£ããªãã³ã«çœå éãŸãã¯å±æç¯æ£æè¡ãªã©ã®çŒæè¡ã«ç¶ããã®ãå«ãè¡åŸççã®æ²»çã«ãæçšã§ããã
ã¹ãè °çãèçãå«ãèçŸæ£ã也ç¬ã湿ç¹ãã¢ã¯ããç±å·ãç®èçãããã³æ¥çŒããå«ã玫å€ç·ç §å°é害ãªã©ã®ç®èé¢é£çŸæ£ããªãã³ã«çœå éãŸãã¯å±æç¯æ£æè¡ãªã©ã®çŒæè¡ã«ç¶ããã®ãå«ãè¡åŸççã®æ²»çã«ãæçšã§ããã
ãããçµæç©ã¯ãççæ§è
žçŸæ£ãã¯ããŒã³ç
ãèçãéææ§è
žçå矀ããã³æœ°çæ§å€§è
žçãªã©ã®æ¶å管çŸæ£ã®æ²»çã«æçšã§ããã
ãããçµæç©ã¯ãåé çãçµç¯æ§åèåšå²çãç²ç¶è ºçãåçäžè¯æ§è²§è¡ãããžãã³ç ã匷ç®çããªã¥ãŠããç±ãåç³å°¿ç ãéççç¡åçãå«ãç¥çµçæ¥åéšçŸæ£ãå€çºæ§ç¡¬åçãå«ãçœè³ªçŸæ£ããµã«ã³ã€ããŒã·ã¹ãããããŒãŒçå矀ãããŒãã§ããçå矀ãå€çºæ§ççãæ¯èçãè çãéæçãè³æµ®è «ãå«ãæå·åŸã«çããè «ããå¿çèè¡ãªã©ã®çŸæ£ã«ãããççã®æ²»çã«æçšã§ããã
ãããçµæç©ã¯ãåé çãçµç¯æ§åèåšå²çãç²ç¶è ºçãåçäžè¯æ§è²§è¡ãããžãã³ç ã匷ç®çããªã¥ãŠããç±ãåç³å°¿ç ãéççç¡åçãå«ãç¥çµçæ¥åéšçŸæ£ãå€çºæ§ç¡¬åçãå«ãçœè³ªçŸæ£ããµã«ã³ã€ããŒã·ã¹ãããããŒãŒçå矀ãããŒãã§ããçå矀ãå€çºæ§ççãæ¯èçãè çãéæçãè³æµ®è «ãå«ãæå·åŸã«çããè «ããå¿çèè¡ãªã©ã®çŸæ£ã«ãããççã®æ²»çã«æçšã§ããã
ãããçµæç©ã¯ã網èçã匷èçãäžåŒ·èçãçµèçã網èçããããŠèçããã
ãæãããã³çŒçµç¹ãžã®æ¥æ§æå·ãªã©ã®çŒçŸæ£ã®æ²»çã«æçšã§ããã
ãããçµæç©ã¯ããŠã€ã«ã¹ææããã³å¢èæ§ç·ç¶çã«äŒŽãèºçã®æ²»çã«ããããŠéªšç²ãããçã䌎ã骚åžåã®æ²»çã«ãããŠæçšã§ããã
ãããçµæç©ã¯ããŠã€ã«ã¹ææããã³å¢èæ§ç·ç¶çã«äŒŽãèºçã®æ²»çã«ããããŠéªšç²ãããçã䌎ã骚åžåã®æ²»çã«ãããŠæçšã§ããã
ãããçµæç©ã¯ãã¢ã«ããã€ããŒç
ãå«ãç®è³ªçŽåãªã©ã®ç¹å®ã®äžæ¢ç¥çµç³»çŸæ£ãç¥çµå€æ§ãããã³ãè³åäžãèè¡ããã³å€å·ã«ç±æ¥ããäžæ¢ç¥çµç³»æå·ã®æ²»çã«æçšã§ãããæ¬æ现æžã«ããã"æ²»ç"ãšããçšèªã¯ãã¢ã«ããã€ããŒç
ãè¡ç®¡æ§çŽåãå€çºæ¢å¡æ§çŽåãåèæçŽåãã¢ã«ã³ãŒã«æ§çŽåããã³è幎æçŽåãå«ãçŽåã®éšåçãŸãã¯ç·åçæå¶ãå«ãã
ãããçµæç©ã¯ãã¢ã¬ã«ã®ãŒæ§éŒ»çãåŒåžçª®è¿«çå矀 ãå
æ¯çŽ æ§ã·ã§ãã¯çå矀ããã³èçŸæ£ã®æ²»çã«æçšã§ããã
ãããçµæç©ã¯ãè¡åŸçŒçãæ¯çãçèçãããã³çã«èµ·å ããçŒçãééå®çã«å«ãçŒçã®æ²»çã«æçšã§ãããäŸãã°ããããçµæç©ã¯ããªã¥ãŠããç±ãã€ã³ãã«ãšã³ã¶ããã³éåžžã®é¢šéªãå«ãä»ã®ãŠã€ã«ã¹ææãé éšããã³èéšçãæçµå°é£çãé çãæ¯çãæ»æ«ããã³æ«å·ãççãç¥çµçãæ»èçãé¢ç¯ç(ãªãŠããæ§é¢ç¯çãå€åœ¢æ§é¢ç¯çŸæ£(å€åœ¢æ§é¢ç¯ç)ãç颚ãããã³åŒ·çŽæ§èæ€çãå«ã)æ»æ¶²å çãç±å·ãããã³å€ç§ããã³æ¯ç§æ²»çåŸã®å€å·ãå«ãã§ãªãçš®ã ã®çŸæ£ã«ãããçŒçãçºç±ããã³ççã®å埩ã®ããã«æçšã§ããã
ãããçµæç©ã¯ãè¡åŸçŒçãæ¯çãçèçãããã³çã«èµ·å ããçŒçãééå®çã«å«ãçŒçã®æ²»çã«æçšã§ãããäŸãã°ããããçµæç©ã¯ããªã¥ãŠããç±ãã€ã³ãã«ãšã³ã¶ããã³éåžžã®é¢šéªãå«ãä»ã®ãŠã€ã«ã¹ææãé éšããã³èéšçãæçµå°é£çãé çãæ¯çãæ»æ«ããã³æ«å·ãççãç¥çµçãæ»èçãé¢ç¯ç(ãªãŠããæ§é¢ç¯çãå€åœ¢æ§é¢ç¯çŸæ£(å€åœ¢æ§é¢ç¯ç)ãç颚ãããã³åŒ·çŽæ§èæ€çãå«ã)æ»æ¶²å çãç±å·ãããã³å€ç§ããã³æ¯ç§æ²»çåŸã®å€å·ãå«ãã§ãªãçš®ã ã®çŸæ£ã«ãããçŒçãçºç±ããã³ççã®å埩ã®ããã«æçšã§ããã
ãããçµæç©ã¯ã被éšè
ã«ãããççæ§å¿è¡ç®¡é害ã®æ²»çããã³äºé²ã«æçšã§ãããããã«éå®ãããªãããããçµæç©ã¯ãè¡ç®¡çŸæ£ãå åèçŸæ£ãåèç€ãè¡ç®¡æ絶ãåè硬åçãå¿è移æ€åŸã®ã¢ãããŒã æ§åè硬åçãå«ãã¢ãããŒã æ§åè硬åçãå¿çæ¢å¡ãå¡æ çãè³åäžãéèè¡æ çãå«ãè¡æ çãäžå®å®çå¿çãå«ãçå¿çãå åèãã©ãŒã¯ã®ççãã¯ã©ããžã¢èªçºæ§ççãå«ã埮çç©èªçºæ§ççããŠã€ã«ã¹èªçºæ§ççãããã³å åèãã€ãã¹è¡ãè¡è¡å建è¡(è¡ç®¡åœ¢æãã¹ãã³ãç眮ãåèå
èåé€ãå«ã)ãŸãã¯åèãéèããã³æ¯çŽ°ç®¡ã«é¢ããä»ã®äŸµè¥²çæè¡ãå«ãè¡ç®¡ç§»æ€è¡ãªã©ã®å€ç§æè¡ã«äŒŽãççã®æ²»çããã³äºé²ã«æçšã§ããã
ãããçµæç©ã¯ãäŸãã°è
«çã®è¡ç®¡æ°çãé»å®³ããã被éšè
ã«ãããè¡ç®¡æ°çé¢é£çŸæ£ã®æ²»çã«æçšã§ããããããã«éå®ãããªãããããçµæç©ã¯ã転移ãå«ãæ°çç©ã®æ²»çã«æçšã§ããïŒè§è移æ€æ絶åå¿ãçŒå
è¡ç®¡æ°çãæå·ãŸãã¯ææã«ç¶ãè¡ç®¡æ°çãå«ãã¬ãããŒã«è¡ç®¡æ°çãç³å°¿ç
æ§ç¶²èçãé»æå€æ§ãåŸæ°Žæ¶äœç·ç¶å¢æ®ããã³æ°çè¡ç®¡ç·å
éãå«ãç·å éïŒè朰çãªã©ã®æœ°çæ§çŸæ£ïŒå¹Œå æ§è¡ç®¡è «ãäžåœé ã®è¡ç®¡ç·ç¶è «ãããã³ç¡è¡ç®¡æ§éªšå£æ»ãå«ãè¡ç®¡è «ãªã©ã®ç çã§ã¯ãããéè «çæ§ã®çŸæ£ïŒããã³åå®®å èçãªã©ã®å¥³æ§çæ®ç³»çŸæ£ã®æ²»çã«æçšã§ããã
éãå«ãç·å éïŒè朰çãªã©ã®æœ°çæ§çŸæ£ïŒå¹Œå æ§è¡ç®¡è «ãäžåœé ã®è¡ç®¡ç·ç¶è «ãããã³ç¡è¡ç®¡æ§éªšå£æ»ãå«ãè¡ç®¡è «ãªã©ã®ç çã§ã¯ãããéè «çæ§ã®çŸæ£ïŒããã³åå®®å èçãªã©ã®å¥³æ§çæ®ç³»çŸæ£ã®æ²»çã«æçšã§ããã
ãããçµæç©ã¯ãçãå«ãè¯æ§è
«çããã³æªæ§è
«ç/æ°çç©ã®äºé²ãŸãã¯æ²»çã«æçšã§
ãããäŸãã°ãçµè žçŽè žçãè³è «çã骚èè «ãåºåºçŽ°èçãªã©ã®äžç®çŽ°èç±æ¥æ°çç©(äž
ç®ç)ãè ºçãå£åçãªã©ã®æ¶ååšçãå£è çãé£éçãå°è žçãèçãçµè žçãèèç
ãèè±çãèµèçãåµå·£çãåå®®é çãèºçãä¹³çããã³æå¹³äžç®çããã³åºåºçŽ°èçãªã©ã®ç®èçãåç«è ºçãè 现èçããã³äœäžã®äžç®çŽ°èãåãä»ã®å ¬ç¥ã®çã«æçšã§ãããæ¬çºæã®çµæç©ããšãããæçšãšèãããããæ²»çã«é©ããæ°çç©ã¯ãæ¶ååšçããã¬ããé£éãèèçãèè±çãèµèçãåµå·£çãåç«è ºçãåå®®é çãèºçãä¹³çããã³æå¹³äžç®çããã³åºåºçŽ°èçãªã©ã®ç®èçã§ãããæ¬çºæã®çµæç©ã¯ãæŸå°è ºæ²»çã«äŒŽãçããç·ç¶çã®æ²»çã«ãæçšã§ããããããçµæç©ã¯ã家ææ§å€§è žç·ç¶ç(FAP)ãæãã被
éšè ãå«ãç·ç¶çããªãŒããæãã被éšè ã®æ²»çã«äœ¿çšããããšãã§ãããããã«ããããçµæç©ã¯ãFAPã®ãªã¹ã¯æ£è ã«ãããŠåœ¢æãããããªãŒããäºé²ããããã«äœ¿çšããã
ãšãã§ããã
ãããäŸãã°ãçµè žçŽè žçãè³è «çã骚èè «ãåºåºçŽ°èçãªã©ã®äžç®çŽ°èç±æ¥æ°çç©(äž
ç®ç)ãè ºçãå£åçãªã©ã®æ¶ååšçãå£è çãé£éçãå°è žçãèçãçµè žçãèèç
ãèè±çãèµèçãåµå·£çãåå®®é çãèºçãä¹³çããã³æå¹³äžç®çããã³åºåºçŽ°èçãªã©ã®ç®èçãåç«è ºçãè 现èçããã³äœäžã®äžç®çŽ°èãåãä»ã®å ¬ç¥ã®çã«æçšã§ãããæ¬çºæã®çµæç©ããšãããæçšãšèãããããæ²»çã«é©ããæ°çç©ã¯ãæ¶ååšçããã¬ããé£éãèèçãèè±çãèµèçãåµå·£çãåç«è ºçãåå®®é çãèºçãä¹³çããã³æå¹³äžç®çããã³åºåºçŽ°èçãªã©ã®ç®èçã§ãããæ¬çºæã®çµæç©ã¯ãæŸå°è ºæ²»çã«äŒŽãçããç·ç¶çã®æ²»çã«ãæçšã§ããããããçµæç©ã¯ã家ææ§å€§è žç·ç¶ç(FAP)ãæãã被
éšè ãå«ãç·ç¶çããªãŒããæãã被éšè ã®æ²»çã«äœ¿çšããããšãã§ãããããã«ããããçµæç©ã¯ãFAPã®ãªã¹ã¯æ£è ã«ãããŠåœ¢æãããããªãŒããäºé²ããããã«äœ¿çšããã
ãšãã§ããã
ãããçµæç©ã¯ãåçž®æ§ããã¹ã¿ãã€ãã®åæãé»å®³ããããšã«ããããã¹ã¿ãã€ãèªçºå¹³æ»çåçž®ãé»å®³ããããããã«ãæçµå°é£çãæ©æååš©ãåæ¯ããã³å¥œé
žçæ§çŸæ£ã®æ²»çã«äœ¿çšã§ããããããçµæç©ã¯ãŸãããšãããéçµæã®å¥³æ§ã«ããã骚éæžå°ã®æå¶(å³ã¡éªšç²ãããçã®æ²»ç)ã«äœ¿çšã§ãããããŠç·å
éã®æ²»çã«äœ¿çšã§ããã
æ¬çºæã®çµæç©ã®å¥œãŸãã䜿çšã¯ããªãŠããæ§é¢ç¯çããã³å€åœ¢æ§é¢ç¯çã®æ²»çãäžè¬çãªçŒçåŠç(ãšããããå£è
æè¡åŸã®çŒçãäžè¬æè¡åŸã®çŒçãæŽåœ¢æè¡åŸã®çŒçãã
ãã³å€åœ¢æ§é¢ç¯çã®æ¿ããçºèµ€)ãã¢ã«ããã€ããŒç ã®æ²»çãããã³çµè žçã®ååŠäºé²ã®
ããã®ãã®ã§ããã
ãã³å€åœ¢æ§é¢ç¯çã®æ¿ããçºèµ€)ãã¢ã«ããã€ããŒç ã®æ²»çãããã³çµè žçã®ååŠäºé²ã®
ããã®ãã®ã§ããã
ããã®æ²»çã«æçšã§ããããšã«å ããŠãæ¬çºæã®çµæç©ã¯ãŸãããããåç©ãå€æ¥åç©ã蟲ååç©ãªã©(ãšãããããã£æ¯åç©ãå«ãåºä¹³åç©)ã®ç£å»æ²»çã«ãæçšã§ãããããã«ç¹å¥ã«ã¯ãæ¬çºæã®çµæç©ã¯ããŠããã€ããããã³ãã³ã«ãããã·ã¯ããªãã·ã²ããŒãŒ2åªä»æ§çŸæ£ã®ç£å»æ²»çã«æçšã§ããã
æ¬çºæã¯ãŸããã·ã¯ããªãã·ã²ããŒãŒ2é»å®³å€ãçšããæ²»çãå¿
èŠãšãããå Žåã®ãç
ç¶ãŸãã¯é害ãåŠçœ®ããæ²»çæ³ã«é¢ãããããè¬å€ãå¿ èŠãšããæ£è ãžã®æ¬çºæã®1çš®é¡
以äžã®çµæç©ã®çµå£æäžãå«ãã§ãªãæ¹æ³ã«é¢ãããçç¶ãŸãã¯é害ã®äºé²ãããã«ç±æ¥ããèŠçã®é€å»ãããã¯æ¹åããããã®æè¬èšç»ã¯ã奜ãŸããã¯ãïŒæ¥ã«ïŒåãããã¯ïŒæ¥ã«ïŒåã®æçšã«å¯Ÿå¿ããããçš®ã ã®å åã«åºã¥ãå€æŽããããšãã§ããããããã®å åã¯ãæ£è ã®äœåã幎霢ãäœéãæ§å¥ãé£é€çæ³ããã³ç æ ãªãã³ã«ãé害ã®æ§è³ªãšé節床ãå«ããåŸã£ãŠãå®éã«çšããæäžèšç»ã¯ãåºãå€åããããšãã§ããããããã«åèšã®å¥œãŸããæäžèšç»ããå€ããå Žåãããã
ç¶ãŸãã¯é害ãåŠçœ®ããæ²»çæ³ã«é¢ãããããè¬å€ãå¿ èŠãšããæ£è ãžã®æ¬çºæã®1çš®é¡
以äžã®çµæç©ã®çµå£æäžãå«ãã§ãªãæ¹æ³ã«é¢ãããçç¶ãŸãã¯é害ã®äºé²ãããã«ç±æ¥ããèŠçã®é€å»ãããã¯æ¹åããããã®æè¬èšç»ã¯ã奜ãŸããã¯ãïŒæ¥ã«ïŒåãããã¯ïŒæ¥ã«ïŒåã®æçšã«å¯Ÿå¿ããããçš®ã ã®å åã«åºã¥ãå€æŽããããšãã§ããããããã®å åã¯ãæ£è ã®äœåã幎霢ãäœéãæ§å¥ãé£é€çæ³ããã³ç æ ãªãã³ã«ãé害ã®æ§è³ªãšé節床ãå«ããåŸã£ãŠãå®éã«çšããæäžèšç»ã¯ãåºãå€åããããšãã§ããããããã«åèšã®å¥œãŸããæäžèšç»ããå€ããå Žåãããã
ã·ã¯ããªãã·ã²ããŒãŒ2é»å®³å€ãçšããæ²»çãå¿
èŠãšãããçç¶ãŸãã¯é害ãæ£ãæ£è
ã®æåã®æ²»çã¯ãåèšã®æäžèšç»ã§ã¯ãããããšãã§ãããæ²»çã¯ãäžè¬çã«èšã£ãŠãå¿ èŠã«å¿ããŠãçç¶ãŸãã¯é害ãæå¶ãŸãã¯é€å»ããããŸã§æ°é±éããæ°ã¶æããããã¯æ°å¹Žã®éç¶ãããæ¬çºæã®çµæç©ãçšããæ²»çãè¡ã£ãŠããæ£è ã¯ãåœæ¥çã«å ¬ç¥ã®ãããã®æ¹æ³ãçšããŠããæ²»çã®æå¹æ§ã枬å®ããããã«ãã«ãŒãã³ã«ã¢ãã¿-ããããšãã§ã
ãããããã¢ãã¿ãªã³ã°ããåŸãããç¶ç¶çãªåæã¯ãæ¬è¬å€ã®é©åãªæå¹éãã©ã®ãããªé©åãªæç¹ã§ãæäžããæ²»çã®æç¶æéã決å®ã§ããããã«æ²»çäžã®æ²»çåŠæ¹èšç»ã®å€æŽãå¯èœã«ããã
ã®æåã®æ²»çã¯ãåèšã®æäžèšç»ã§ã¯ãããããšãã§ãããæ²»çã¯ãäžè¬çã«èšã£ãŠãå¿ èŠã«å¿ããŠãçç¶ãŸãã¯é害ãæå¶ãŸãã¯é€å»ããããŸã§æ°é±éããæ°ã¶æããããã¯æ°å¹Žã®éç¶ãããæ¬çºæã®çµæç©ãçšããæ²»çãè¡ã£ãŠããæ£è ã¯ãåœæ¥çã«å ¬ç¥ã®ãããã®æ¹æ³ãçšããŠããæ²»çã®æå¹æ§ã枬å®ããããã«ãã«ãŒãã³ã«ã¢ãã¿-ããããšãã§ã
ãããããã¢ãã¿ãªã³ã°ããåŸãããç¶ç¶çãªåæã¯ãæ¬è¬å€ã®é©åãªæå¹éãã©ã®ãããªé©åãªæç¹ã§ãæäžããæ²»çã®æç¶æéã決å®ã§ããããã«æ²»çäžã®æ²»çåŠæ¹èšç»ã®å€æŽãå¯èœã«ããã
ãã®ããã«ããŠãååãªå¹æã瀺ãè¬ç©ã®æäœéãæäžããçç¶ãŸãã¯é害ãæå¹ã«æ²»çããã®ã«ååãªæéã«ã ãæäžãç¶ããããã«ãæ²»çåŠæ¹èšç»ãšæäžèšç»ãæ²»çæéã«ããã£ãŠåççã«ä¿®æ£ããããšãã§ããã
æ¬çµæç©ã¯ããšãããã麻è¬æ§é®çå€ãÎŒå容äœã¢ã³ã¿ãŽãã¹ããκå容äœã¢ã³ã¿ãŽãã¹ããé麻è¬æ§(å³ã¡ãåžžç¿æ§ã®ãªã)é®çå€ãã¢ãã¢ãã³åã蟌ã¿é»å®³å€ãã¢ããã·ã³èª¿ç¯å€ãã«ã³ãããã€ãèªå°äœããµãã¹ã¿ã³ã¹Pã¢ã³ã¿ãŽãã¹ãããã¥ãŒãããã³1å容äœã¢ã³ã¿ãŽãã¹ãããã³ãããªãŠã ãã£ã³ãã«é®æè¬ãå«ãããªããªã€ãããã³ä»ã®é®çå€ãšã®äœµçšçæ³ã§çšããããšãã§ããã奜ãŸãã䜵çšçæ³ã¯ãã¢ã»ã¯ããã§ãã¯ãã¢ã»ã¡ã¿ã·ã³ãε-ã¢ã»ãã¢ããã«ããã³é
žãã¢ã»ãã¢ãããã§ã³ãã¢ã»ãã¢ããªããã¢ã»ãã«ãµãª
ãã«é ž(ã¢ã¹ããªã³)ã-ã¢ããã·ã«ã¡ããªãã³ãã¢ã«ã¯ããã§ããã¯ãã¢ã«ãã§ã³ã¿ã
ã«ãã¢ãªã«ãããžã³ãã¢ã«ãããããã§ã³ãã¢ããã·ããªã³ãã¢ã«ãã¡ãããžã³ããã¹(
ã¢ã»ãã«ãµãªãã«é ž)ã¢ã«ãããŠã ãã¢ã ãã§ããã¯ãã¢ããã¯ããããããµãžã³ãïŒâ
ã¢ããâïŒâããããã·é ªé žãïŒâã¢ããâïŒâãã³ãªã³ãã¢ããããããã³ãã¢ããããªã³ãã¢ããã»ããªã³ããµãªãã«é žã¢ã³ã¢ããŠã ãã¢ã³ãããã·ã«ã ãã¢ã³ãã«ã¡ãã³ã°ã¢ã·ã«ãã¢ãã¬ãªãžã³ãã¢ã³ãããªã³ããµãªãã«é žã¢ã³ãããªã³ãã¢ã³ãã©ãã§ãã³ãã¢ããŸã³ããã³ãã¶ãã¯ããããªã©ãŒããããããµãããã§ã³ããã³ãŸãããªãã³ããã³ãžããã³ããã³ãžã«ã¢ã«ããããã«ã¢ãããã§ã³ãããžãã©ãããαâããµãããŒã«ãããã¢ãã§ããã¯ãïœâããã¢ã¢ã»ãã¢ããªããé ¢é žïŒâããã¢é ¢é žãããã¢ãµãªã²ãã³ããã¯ããã·é žããã³ããŒã ãããã§ããµããã¯ããããã£ãŸã³ãããã¬ãã«ãã£ã³ããã¿ã»ãã³ãããããã§ã³ããããã¡ããŒã«ãã¢ã»ãã«ãµãªãã«é žã«ã«ã·ãŠã ãã«ã«ãããŒãã³ãã«ã«ããã§ã³ãã«ã«ãããã§ã³ãã«ã«ãµã©ã ãã¯ãããã¿ããŒã«ãã¯ããããããµãžã³ããµãªãã«é žã³ãªã³ãã·ã³ã³ãã§ã³ãã·ã³ã¡ã¿ã·ã³ãã·ã©ãããŒã«ãã¯ãªããã¯ãã¯ãã¡ã¿ã·ã³ãã¯ããã¿ãŒã³ãã¯ãããã·ã³ãã¯ããã©ãã¯ãã¯ããŒããã³ãã€ã³ãããã¢ã¡ãã«ã³ãã€ã³ããªã³é žã³ãã€ã³ãç¡«é žã³ãã€ã³ãã¯ãããããããã¯ããã¿ãããããœã¢ã«ããããããœããµãããŒã«ãããã¹ããã¢ã©ãããããŸã·ã³ããžã¢ã ããããããžã¯ããã§ãã¯ãããªãŠã ããžãã§ãããŸãŒã«ããžãã§ã³ãã©ããããžãã«ããµã«ããžãããã³ãã€ã³ããžãããã³ãã€ãã³ãšããŒã«ã¢ã»ããŒãããžãããã¢ã«ãããã¢ã»ãã«ãµãªãã«é žãžããããã·ã¢ã«ãããŠã ããžã¡ãããµããŒã«ããžã¡ãã§ãã¿ããŒã«ããžã¡ãã«ãã¢ã³ããã³ããžãªããµãã§ãã«ãé ªé žãžãªããµãã§ãã«ããžãããã³ããžããã»ãã«ããžããã³ããžã¿ãŸãŒã«ããããã·ã«ã ããšã¢ã«ãã¡ãŸã³ããšã³ãã§ããã³é žããšããªãŸãŒã«ããšãã¿ãŸã·ã³ããšãã«ãµã¬ãŒãããšãã³ã¶ããããšãããã¿ãžã³ããšãããµãŒã³ããšãã«ã¡ãã«ãã¢ã³ããã³ããšãã«ã¢ã«ããããšããã©ã¯ããšããã§ãã¡ãŒãããšããã¿ãŒã³ããªã€ã²ããŒã«ããã§ã«ããã¯ããã§ã³ããã§ã³ããã§ã³ã¯ããžã³é žããã§ã³ããµã«ããã§ããããã§ã³ããã§ã³ã¿ãã«ããã§ã³ãã¢ã¶ã¯ããã§ãã©ãžããŒã«ããã§ãã©ãŸã³ãããã¯ã¿ãã§ãã³ããã«ãã§ããã³é žããã«ãããµãããã§ã³ããã«ãªã¬ãŸã³ããã«ãã«ãã³ããã«ããã¯ã¢ãŸã³ããã«ã«ããããã§ã³ããã©ã¹ãã©ãµã«ãã²ã³ããžã³é žãã°ã©ãã§ãã³ãã°ã«ã«ã¡ã¿ã·ã³ããµãªãã«é žã°ãªã³ãŒã«ãã°ã¢ã€ã¢ãºã¬ã³ããããã³ãã³ããããã¢ã«ãã³ãããããã·ãããžã³ãã€ããã§ãã¯ãã€ããããã§ã³ãã€ãããããµã ããµãªãã«é žã€ãããŸãŒã«ãã€ã³ãã¡ã¿ã·ã³ãã€ã³ããããã§ã³ãã€ãœãã§ãŸã©ã¯ãã€ãœã©ããŒã«ãã€ãœã¡ã¿ãã³ãã€ãœããã·ã³ãã€ãœãã»ãã¯ãã€ãœãã·ã«ã ãã±ããããã³ãã±ããããã§ã³ãã±ããã©ã¯ãïœâã©ã¯ããã§ããããã¬ãã§ã¿ãã³ãã¬ãã«ãã¡ããŒã«ãããã§ã³ã¿ãã«ããããŸã©ã¯ããã«ããã·ã«ã ããããœãããã§ã³ãã¢ã»ãã«ãµãªãã«é žãªãžã³ãã¢ã»ãã«ãµãªãã«é žãã°ãã·ãŠã ãã¡ã¯ããã§ããã³é žãã¡ãã§ããã³é žãã¡ããªãžã³ãã¡ãã¿ãžããŒã«ãã¡ãµã©ãã³ãã¡ã¿ãŸã·ã³ãã¡ã¿ãã³å¡©é žå¡©ãã¡ãã¢ãžãã³é žãã¡ããã©ãªã³ãã¡ããã³ãã¢ãã§ãã¿ãŸã³ãã¢ãã§ãŸã©ã¯ãã¢ã©ãŸã³ãã¢ã«ãããã¢ã«ããå¡©é žå¡©ãã¢ã«ããç¡«é žå¡©ããµãªãã«é žã¢ã«ããªã³ããããã£ã³ãããã¡ãã³ããã«ããã£ã³ããµãªãã«é žïŒâãããã«ãããããã»ã³ããã«ã»ã€ã³ãããã©ãã ããã³ã¢ã«ãããããã§ããŸã³ãããã«ãã³é žããã¡ã¹ãªããïŒ'âãããâïŒ'âããããã·ã¢ã»ãã¢ããªãããã«ã¬ãã«ãã¡ããŒã«ããã«ã¡ã¿ãã³ããã«ã¢ã«ããããã«ãããã³ããªã«ãµã©ãžã³ãã¢ãã³
ããªããµã»ãããŒã«ããªããµã¡ã¿ã·ã³ããªããµãããžã³ããªãã·ã³ãã³ããªãã·ã¢ã«ãã³ããªãã·ãã§ã³ãã¿ãŸã³ããããã¬ãã ããã©ããªã³ããã«ãµã«ããããã³ã¿ãŸã·ã³ãããªãœããµã«ããã§ãã»ãã³ããã§ããããœã³ããã§ããŸã·ã³ããã§ããŸããªãžã³å¡©é žå¡©ããã§ãã³ãŒã«ããã§ãããªãžã³ããã§ããã©ãŸã³ãã¢ã»ãã«ãµãªãã«é žãã§ãã«ããã§ãã«ãã¿ãŸã³ããµãªãã«é žãã§ãã«ããã§ãã©ãããŒã«ããã±ããããã§ã³ãããããžã³ãããããŸã³ããããªãã³ãããããã§ã³ããã©ãŸã©ã¯ãããªãã©ããããããã·ã«ã ããã©ããããã§ã³ãããã°ã«ã¡ã¿ã·ã³ãããããã¿ãžã³ãããã¡ããŒã«ããããã»ã¿ã¢ãŒã«ããããã©ã ãããããã·ãã§ã³ãããããã§ããŸã³ãããã¯ã¢ãŸã³ãããããžã³é žãã©ããã§ããŸã³ãã¬ããã§ã³ã¿ãã«ãã¡ãã«ç¡«é žãªããŸãªãŠã ããµã©ã»ã¿ããããµãªã·ã³ããµãªãã«ã¢ããããµãªãã«ã¢ãão-é ¢é žããµãªãã«ç¡«é žããµã«ãµã«ãããµã«ããªã³ãã·ã¡ããªãããµãªãã«é žãããªãŠã ãã¹ãã§ã³ã¿ãã«ãã¹ã«ãã¡ãµã©ãžã³ãã¹ãªã³ããã¯ãã¹ãŒããŒãªãã·ããžã¹ã ã¿ãŒãŒãã¹ãããã§ã³ãã¹ã¯ã·ããŸã³ãã¿ã«ããã«ã¡ãŒããããããããããã·ã«ã ããããã§ãã¡ãŒããããã©ã³ããªã³ããã¢ãŸãªããã¿ãŸã³ããã¢ãããã§ã³é žããã¢ã©ãããããªãžã³ããããªãžã³ããã«ãã§ããã³é žããã«ã¡ãã³ããã©ãããŒã«ããããã·ã³ãããããŒã«ããã»ã³ãã·ã³ããã·ã¢ãããã§ã³ãã¶ã«ããããã§ã³ããã³ãŸã¡ãã©ãã¯ããéžæããã1çš®é¡ä»¥äžã®ååç©ãšæ¬çºæã®çµæç©ã®äœ¿çšãå«ã(The Merck Index, 第ïŒïŒç(1996ïŒãTherapeutic Category and Biological Activity Index,ãšããã«æ²èŒãããŠãã"é®çå€âã"æççå€"ãããã³â解ç±å€âãšããèŠåºãã®è¡šãåç §ã®äº)ã
ãã«é ž(ã¢ã¹ããªã³)ã-ã¢ããã·ã«ã¡ããªãã³ãã¢ã«ã¯ããã§ããã¯ãã¢ã«ãã§ã³ã¿ã
ã«ãã¢ãªã«ãããžã³ãã¢ã«ãããããã§ã³ãã¢ããã·ããªã³ãã¢ã«ãã¡ãããžã³ããã¹(
ã¢ã»ãã«ãµãªãã«é ž)ã¢ã«ãããŠã ãã¢ã ãã§ããã¯ãã¢ããã¯ããããããµãžã³ãïŒâ
ã¢ããâïŒâããããã·é ªé žãïŒâã¢ããâïŒâãã³ãªã³ãã¢ããããããã³ãã¢ããããªã³ãã¢ããã»ããªã³ããµãªãã«é žã¢ã³ã¢ããŠã ãã¢ã³ãããã·ã«ã ãã¢ã³ãã«ã¡ãã³ã°ã¢ã·ã«ãã¢ãã¬ãªãžã³ãã¢ã³ãããªã³ããµãªãã«é žã¢ã³ãããªã³ãã¢ã³ãã©ãã§ãã³ãã¢ããŸã³ããã³ãã¶ãã¯ããããªã©ãŒããããããµãããã§ã³ããã³ãŸãããªãã³ããã³ãžããã³ããã³ãžã«ã¢ã«ããããã«ã¢ãããã§ã³ãããžãã©ãããαâããµãããŒã«ãããã¢ãã§ããã¯ãïœâããã¢ã¢ã»ãã¢ããªããé ¢é žïŒâããã¢é ¢é žãããã¢ãµãªã²ãã³ããã¯ããã·é žããã³ããŒã ãããã§ããµããã¯ããããã£ãŸã³ãããã¬ãã«ãã£ã³ããã¿ã»ãã³ãããããã§ã³ããããã¡ããŒã«ãã¢ã»ãã«ãµãªãã«é žã«ã«ã·ãŠã ãã«ã«ãããŒãã³ãã«ã«ããã§ã³ãã«ã«ãããã§ã³ãã«ã«ãµã©ã ãã¯ãããã¿ããŒã«ãã¯ããããããµãžã³ããµãªãã«é žã³ãªã³ãã·ã³ã³ãã§ã³ãã·ã³ã¡ã¿ã·ã³ãã·ã©ãããŒã«ãã¯ãªããã¯ãã¯ãã¡ã¿ã·ã³ãã¯ããã¿ãŒã³ãã¯ãããã·ã³ãã¯ããã©ãã¯ãã¯ããŒããã³ãã€ã³ãããã¢ã¡ãã«ã³ãã€ã³ããªã³é žã³ãã€ã³ãç¡«é žã³ãã€ã³ãã¯ãããããããã¯ããã¿ãããããœã¢ã«ããããããœããµãããŒã«ãããã¹ããã¢ã©ãããããŸã·ã³ããžã¢ã ããããããžã¯ããã§ãã¯ãããªãŠã ããžãã§ãããŸãŒã«ããžãã§ã³ãã©ããããžãã«ããµã«ããžãããã³ãã€ã³ããžãããã³ãã€ãã³ãšããŒã«ã¢ã»ããŒãããžãããã¢ã«ãããã¢ã»ãã«ãµãªãã«é žãžããããã·ã¢ã«ãããŠã ããžã¡ãããµããŒã«ããžã¡ãã§ãã¿ããŒã«ããžã¡ãã«ãã¢ã³ããã³ããžãªããµãã§ãã«ãé ªé žãžãªããµãã§ãã«ããžãããã³ããžããã»ãã«ããžããã³ããžã¿ãŸãŒã«ããããã·ã«ã ããšã¢ã«ãã¡ãŸã³ããšã³ãã§ããã³é žããšããªãŸãŒã«ããšãã¿ãŸã·ã³ããšãã«ãµã¬ãŒãããšãã³ã¶ããããšãããã¿ãžã³ããšãããµãŒã³ããšãã«ã¡ãã«ãã¢ã³ããã³ããšãã«ã¢ã«ããããšããã©ã¯ããšããã§ãã¡ãŒãããšããã¿ãŒã³ããªã€ã²ããŒã«ããã§ã«ããã¯ããã§ã³ããã§ã³ããã§ã³ã¯ããžã³é žããã§ã³ããµã«ããã§ããããã§ã³ããã§ã³ã¿ãã«ããã§ã³ãã¢ã¶ã¯ããã§ãã©ãžããŒã«ããã§ãã©ãŸã³ãããã¯ã¿ãã§ãã³ããã«ãã§ããã³é žããã«ãããµãããã§ã³ããã«ãªã¬ãŸã³ããã«ãã«ãã³ããã«ããã¯ã¢ãŸã³ããã«ã«ããããã§ã³ããã©ã¹ãã©ãµã«ãã²ã³ããžã³é žãã°ã©ãã§ãã³ãã°ã«ã«ã¡ã¿ã·ã³ããµãªãã«é žã°ãªã³ãŒã«ãã°ã¢ã€ã¢ãºã¬ã³ããããã³ãã³ããããã¢ã«ãã³ãããããã·ãããžã³ãã€ããã§ãã¯ãã€ããããã§ã³ãã€ãããããµã ããµãªãã«é žã€ãããŸãŒã«ãã€ã³ãã¡ã¿ã·ã³ãã€ã³ããããã§ã³ãã€ãœãã§ãŸã©ã¯ãã€ãœã©ããŒã«ãã€ãœã¡ã¿ãã³ãã€ãœããã·ã³ãã€ãœãã»ãã¯ãã€ãœãã·ã«ã ãã±ããããã³ãã±ããããã§ã³ãã±ããã©ã¯ãïœâã©ã¯ããã§ããããã¬ãã§ã¿ãã³ãã¬ãã«ãã¡ããŒã«ãããã§ã³ã¿ãã«ããããŸã©ã¯ããã«ããã·ã«ã ããããœãããã§ã³ãã¢ã»ãã«ãµãªãã«é žãªãžã³ãã¢ã»ãã«ãµãªãã«é žãã°ãã·ãŠã ãã¡ã¯ããã§ããã³é žãã¡ãã§ããã³é žãã¡ããªãžã³ãã¡ãã¿ãžããŒã«ãã¡ãµã©ãã³ãã¡ã¿ãŸã·ã³ãã¡ã¿ãã³å¡©é žå¡©ãã¡ãã¢ãžãã³é žãã¡ããã©ãªã³ãã¡ããã³ãã¢ãã§ãã¿ãŸã³ãã¢ãã§ãŸã©ã¯ãã¢ã©ãŸã³ãã¢ã«ãããã¢ã«ããå¡©é žå¡©ãã¢ã«ããç¡«é žå¡©ããµãªãã«é žã¢ã«ããªã³ããããã£ã³ãããã¡ãã³ããã«ããã£ã³ããµãªãã«é žïŒâãããã«ãããããã»ã³ããã«ã»ã€ã³ãããã©ãã ããã³ã¢ã«ãããããã§ããŸã³ãããã«ãã³é žããã¡ã¹ãªããïŒ'âãããâïŒ'âããããã·ã¢ã»ãã¢ããªãããã«ã¬ãã«ãã¡ããŒã«ããã«ã¡ã¿ãã³ããã«ã¢ã«ããããã«ãããã³ããªã«ãµã©ãžã³ãã¢ãã³
ããªããµã»ãããŒã«ããªããµã¡ã¿ã·ã³ããªããµãããžã³ããªãã·ã³ãã³ããªãã·ã¢ã«ãã³ããªãã·ãã§ã³ãã¿ãŸã³ããããã¬ãã ããã©ããªã³ããã«ãµã«ããããã³ã¿ãŸã·ã³ãããªãœããµã«ããã§ãã»ãã³ããã§ããããœã³ããã§ããŸã·ã³ããã§ããŸããªãžã³å¡©é žå¡©ããã§ãã³ãŒã«ããã§ãããªãžã³ããã§ããã©ãŸã³ãã¢ã»ãã«ãµãªãã«é žãã§ãã«ããã§ãã«ãã¿ãŸã³ããµãªãã«é žãã§ãã«ããã§ãã©ãããŒã«ããã±ããããã§ã³ãããããžã³ãããããŸã³ããããªãã³ãããããã§ã³ããã©ãŸã©ã¯ãããªãã©ããããããã·ã«ã ããã©ããããã§ã³ãããã°ã«ã¡ã¿ã·ã³ãããããã¿ãžã³ãããã¡ããŒã«ããããã»ã¿ã¢ãŒã«ããããã©ã ãããããã·ãã§ã³ãããããã§ããŸã³ãããã¯ã¢ãŸã³ãããããžã³é žãã©ããã§ããŸã³ãã¬ããã§ã³ã¿ãã«ãã¡ãã«ç¡«é žãªããŸãªãŠã ããµã©ã»ã¿ããããµãªã·ã³ããµãªãã«ã¢ããããµãªãã«ã¢ãão-é ¢é žããµãªãã«ç¡«é žããµã«ãµã«ãããµã«ããªã³ãã·ã¡ããªãããµãªãã«é žãããªãŠã ãã¹ãã§ã³ã¿ãã«ãã¹ã«ãã¡ãµã©ãžã³ãã¹ãªã³ããã¯ãã¹ãŒããŒãªãã·ããžã¹ã ã¿ãŒãŒãã¹ãããã§ã³ãã¹ã¯ã·ããŸã³ãã¿ã«ããã«ã¡ãŒããããããããããã·ã«ã ããããã§ãã¡ãŒããããã©ã³ããªã³ããã¢ãŸãªããã¿ãŸã³ããã¢ãããã§ã³é žããã¢ã©ãããããªãžã³ããããªãžã³ããã«ãã§ããã³é žããã«ã¡ãã³ããã©ãããŒã«ããããã·ã³ãããããŒã«ããã»ã³ãã·ã³ããã·ã¢ãããã§ã³ãã¶ã«ããããã§ã³ããã³ãŸã¡ãã©ãã¯ããéžæããã1çš®é¡ä»¥äžã®ååç©ãšæ¬çºæã®çµæç©ã®äœ¿çšãå«ã(The Merck Index, 第ïŒïŒç(1996ïŒãTherapeutic Category and Biological Activity Index,ãšããã«æ²èŒãããŠãã"é®çå€âã"æççå€"ãããã³â解ç±å€âãšããèŠåºãã®è¡šãåç §ã®äº)ã
ãšããã奜ãŸãã䜵çšçæ³ã¯ãæ¬ã¯çºæã®çµæç©(äŸãã°æ¬çºæã®ãã«ãã³ãã·ãçµæ
ç©)ãšããªããªã€ãååç©(ããã«ç¹å¥ã«ã¯ãªããªã€ãååç©ãã³ãã€ã³ãã¡ããªãžã³ãã¢ã«ãããŸãã¯ãã®èªå°äœãªã©ã®å Žå)ã®äœ¿çšãå«ãã
ç©)ãšããªããªã€ãååç©(ããã«ç¹å¥ã«ã¯ãªããªã€ãååç©ãã³ãã€ã³ãã¡ããªãžã³ãã¢ã«ãããŸãã¯ãã®èªå°äœãªã©ã®å Žå)ã®äœ¿çšãå«ãã
ãã«ãã³ãã·ããšäœµçšã§æäžãããååç©ã¯ããã«ãã³ãã·ããšåé¢ããŠè£œå€åããããšãã§ãããããããã¯æ¬çºæã®çµæç©äžã®ãã«ãã³ãã·ããšäžç·ã«è£œå€åããããšãã§ããããã«ãã³ãã·ããäŸãã°ãªããªã€ãè¬ç©ãªã©ã®ããïŒã€ã®è¬ç©ãšäžç·ã«è£œå€åãããå Žåããã®ããïŒã€ã®è¬ç©ã¯ãå³ææŸåºãæ¥éãªäœçšéå§ãåŸæŸæ§ãŸãã¯äºå
æŸåºæ§ã®åœ¢ã§è£œå€åã§ããã
æ¬çºæã®ïŒã€ã®å®æœæ
æ§ã«ãããŠããšãããã·ã¯ããªãã·ã²ããŒãŒïŒåªä»æ§çç¶ãé çãŸãã¯çé çã®å Žåãè¡ç®¡èª¿ç¯å€ã奜ãŸããã¯è¡ç®¡èª¿ç¯äœçšãæããããµã³ãã³èªå°äœãããã«å¥œãŸããã¯ã¢ã«ãã«ããµã³ãã³ååç©ãšã®äœµçšçæ³ã§ãã«ãã³ãã·ãçµæç©ãæäžãããã
æ¬æ现æžã«èšèŒãããŠãããããªã¢ã«ãã«ããµã³ãã³ååç©ããã«ãã³ãã·ãçµæç©ãšåææäžããã䜵çšçæ³ã¯ãã¢ã«ãã«ããµã³ãã³ãè¡ç®¡èª¿ç¯å€ã§ãããã©ããããããã¯äœµçšå€ã®æ²»çå¹æãè¡ç®¡èª¿ç¯å¹æã«ã©ã®çšåºŠè²¢ç®ããŠãããã©ããã«ããããããæ¬çºæã®å®æœæ
æ§ã«å«ãŸãããæ¬æ现æžã«ããã"ã¢ã«ãã«ããµã³ãã³"ãšããçšèªã¯ãïŒçš®é¡ä»¥äžã®C1-4ã¢ã«ãã«(奜ãŸããã¯ã¡ãã«)眮æåºãæããããµã³ãã³èªå°äœãããã³ãããããµã³ãã³èªå°äœã®è¬åŠçã«èš±å®¹ãããå¡©ãå«ããã«ãã§ã€ã³ãããªãããã³ããã³ããªãã£ãªã³ãå«ããžã¡ãã«ããµã³ãã³é¡ããã³ããªã¡ãã«ããµã³ãã³é¡ããšããã奜ãŸãããæã奜ãŸããã¯ãã¢ã«ãã«ããµã³ãã³ååç©ã¯ã«ãã§ã€ã³ã§ããã
ãã«ãã³ãã·ãããã³è¡ç®¡èª¿ç¯å€ãŸãã¯ã¢ã«ãã«ããµã³ãã³ã®æäžã®ç·éãŸãã¯çžå¯Ÿéã¯ãé çãŸãã¯çé çã«é¢é£ããçŒç軜æžã®æ²»çå¹æãæããããã³/ãŸãã¯äºé²å¹æã
æããæ§ã«éžæããããé©åãªæäžéã¯ãé çã®é節床ããã³ç¹å®ã®è¡ç®¡èª¿ç¯å€ãŸãã¯éžæãããã¢ã«ãã«ããµã³ãã³ã«ãã£ãŠæ±ºãŸããäŸãã°ããã«ãã³ãã·ããšã«ãã§ã€ã³ã®äœµçšçæ³ã«ãããŠãäžè¬çã«ããã«ãã³ãã·ãã¯çŽ1mgãã100mgã®äžæ¥éã§ã奜ãŸããã¯çŽ5mgãã50mgã§ããããŠã«ãã§ã€ã³ã¯çŽ1mgããçŽ500mgã®äžæ¥éã§ã奜ãŸããã¯çŽ10mgã
ãçŽ400mgã§ãããã«å¥œãŸããã¯çŽ20mgããçŽ300mgã§æäžãããã
æããæ§ã«éžæããããé©åãªæäžéã¯ãé çã®é節床ããã³ç¹å®ã®è¡ç®¡èª¿ç¯å€ãŸãã¯éžæãããã¢ã«ãã«ããµã³ãã³ã«ãã£ãŠæ±ºãŸããäŸãã°ããã«ãã³ãã·ããšã«ãã§ã€ã³ã®äœµçšçæ³ã«ãããŠãäžè¬çã«ããã«ãã³ãã·ãã¯çŽ1mgãã100mgã®äžæ¥éã§ã奜ãŸããã¯çŽ5mgãã50mgã§ããããŠã«ãã§ã€ã³ã¯çŽ1mgããçŽ500mgã®äžæ¥éã§ã奜ãŸããã¯çŽ10mgã
ãçŽ400mgã§ãããã«å¥œãŸããã¯çŽ20mgããçŽ300mgã§æäžãããã
䜵çšçæ³ã®è¡ç®¡èª¿ç¯å€ãŸãã¯ã¢ã«ãã«ããµã³ãã³æåã¯ãä»»æã®é©åãªè£œå€ã§ãä»»æã®æäžçµè·¯ã«ããæäžã§ãããã奜ãŸããã¯çµå£æäžã§æäžããããè¡ç®¡èª¿ç¯å€ãããã¯ã¢ã«ãã«ããµã³ãã³ã¯ãææã«ãããæ¬çºæã®æ圢åã«ããã«ãã³ãã·ããšæ··å補å€åã§ãããåŸã£ãŠãæ¬çºæã®æ圢åã¯ãææã«ãããåèšã®æäžéãšäžèŽããç·éããã³çžå¯Ÿéã§ããã«ãã³ãã·ãããã³è¡ç®¡èª¿ç¯å€ãŸãã¯ã«ãã§ã€ã³ãªã©ã®ã¢ã«ãã«ããµã³ãã³ã®äž¡æ¹ãå«ãã
æ¬å®æœæ
æ§ã®çµæç©ã«ãããããã«ãã³ãã·ãããã³è¡ç®¡èª¿ç¯å€ãŸãã¯ã¢ã«ãã«ããµã³ãã³ã®éã«é¢ãããâçŒçã軜æžããããã«æå¹ãªç·éããã³çžå¯Ÿéã§âãšããçšèªã¯ããããã®éãã(a) ãããäž¡æ¹ã®æåãçŒçã®è»œæžã«æå¹ã§ããããããŠ(b) ããäžæ¹ã®æåãããããçç¶ã軜æžããããã«ååãªéååšããªãããããã¯ååšããªãã ãããšèããããå Žåãåæåã¯ãé ç軜æžå¹æã«è²¢ç®ã§ããããããã¯ã§ããã ãããšæåŸ
ãããããããªéãæå³ããã
ïŒå®æœäŸ)
以äžã®å®æœäŸã«æ¬çºæã®åŽé¢ãäŸç€ºãããããããå¶éãšè§£éããŠã¯ãªããªãã
å®æœäŸ1
ãã«ãã³ãã·ãé溶é (ãããAã以åŸãããé溶é AãšãåŒã¶)ã以äžã®æ¹æ³ã«åŸã£ãŠè£œé ããããã«ãã³ãã·ã(950g)ãšã³ãã€ãç¶äºé žåçªçŽ (50g)ãå ±ã«è£œç²ããè¬å€ç²æ«ã
äœæãããã©ãŠãªã«ç¡«é žãããªãŠã (SLSïŒ2ïŒ5g)ãã¢ã»ã¹ã«ãã¡ã K(9g)ããã³ãããŒã«(300g)ãããã³ãã«ããŒã¹(75g)ãæ°Žã«60âã§æº¶è§£ããã¹ãã¬ãŒæ¶²ãäœæãããè¬å€é¡ç²ãäœæããããã«ã以äžã®æ¡ä»¶ã§ã¹ãã¬ãŒæ¶²ãçšããŠè¬å€ç²æ«ãæµåå±€é ç²ããïŒå°å ¥ç©ºæ°æž©åºŠïŒ70âïŒå°å ¥ç©ºæ°é 10-30CFMïŒã¹ãã¬ãŒé床ïŒ30g/åãè¬å€é¡ç²ã®çµæãè¡š1ã«ç€º
ãã
以äžã®å®æœäŸã«æ¬çºæã®åŽé¢ãäŸç€ºãããããããå¶éãšè§£éããŠã¯ãªããªãã
å®æœäŸ1
ãã«ãã³ãã·ãé溶é (ãããAã以åŸãããé溶é AãšãåŒã¶)ã以äžã®æ¹æ³ã«åŸã£ãŠè£œé ããããã«ãã³ãã·ã(950g)ãšã³ãã€ãç¶äºé žåçªçŽ (50g)ãå ±ã«è£œç²ããè¬å€ç²æ«ã
äœæãããã©ãŠãªã«ç¡«é žãããªãŠã (SLSïŒ2ïŒ5g)ãã¢ã»ã¹ã«ãã¡ã K(9g)ããã³ãããŒã«(300g)ãããã³ãã«ããŒã¹(75g)ãæ°Žã«60âã§æº¶è§£ããã¹ãã¬ãŒæ¶²ãäœæãããè¬å€é¡ç²ãäœæããããã«ã以äžã®æ¡ä»¶ã§ã¹ãã¬ãŒæ¶²ãçšããŠè¬å€ç²æ«ãæµåå±€é ç²ããïŒå°å ¥ç©ºæ°æž©åºŠïŒ70âïŒå°å ¥ç©ºæ°é 10-30CFMïŒã¹ãã¬ãŒé床ïŒ30g/åãè¬å€é¡ç²ã®çµæãè¡š1ã«ç€º
ãã
é Aã¯ãã«ãŒããŒãã¬ã¹(carver press)ã§400mgã®æé çšæ··åç©ãå§çž®ããŠäœæãããé溶é Aã®çµæãè¡š2ã«ç€ºãã
ããŒã°ã«ç¬ã«ãããããã«ãã³ãã·ãé溶é Aã®è¬ç©åæ åŠçæ§è³ªã枬å®ããããã«ã
ç 究ãè¡ã£ãããã«ãã³ãã·ãé溶é Aã4å¹ã®ã€ãã®ããããã«æäžãããçµå£æäžã®æäžåãããã³çµå£æäžã®ã0ïŒ5ã1ã1ïŒ5ã2ã2ïŒ5ã3ã4ãïŒãïŒã12ãããã³24æéåŸã«ãéèè¡ãæ¡åããã3000Gã®é å¿åé¢ã«ããè¡æ¶²ããè¡æŒ¿ãåé¢ãããã®ãµã³ãã«ã
åæãŸã§â20âã§ä¿åãããè¡æž äžã®ãã«ãã³ãã·ãã®æ¿åºŠããHPLCåæãçšããŠæž¬å®ãããçµæãè¡š3ã«ç€ºãã
ãã«ãã³ãã·ãé溶é (ãããBã以åŸé溶é BãšãåŒã¶)ã以äžã®æ¹æ³ã«åŸã£ãŠè£œé ããããã«ãã³ãã·ããšã³ãã€ãç¶äºé žåçªçŽ ãäžç·ã«ç²æ«åããè¬å€ç²æ«ãäœæãããã©ãŠãªã«ç¡«é žãããªãŠã ãã¢ã»ã¹ã«ãã¡ã Kããã³ãããŒã«ãããã³ãã«ããŒã¹ã60â以äžã«
ç¶æããæ°Žã«æº¶è§£ããã¹ãã¬ãŒæ¶²ãäœæãããè¬å€é¡ç²ãäœæããããã«ãè¬å€ç²æ«ãã以äžã®æ¡ä»¶ã§ã¹ãã¬ãŒæ¶²ãçšããŠæµåå±€é ç²ããïŒå°å ¥ç©ºæ°æž©åºŠïŒ70âïŒå°å ¥ç©ºæ°éïŒ10-30CFMïŒã¹ãã¬ãŒé床ïŒ30g/åãè¬å€é¡ç²ã®çµæãè¡š4ã«ç€ºãã
ããã7%ãã«ããŒã¹ãé ç²ãããã®ãå«ã)ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã¹ãã¢ãªã³é ž
ãã¢ã»ã¹ã«ãã¡ã Kãããã³ãããŒãã³ããæ··åããæé çšæ··åç©ãäœæãããé溶é Bã¯ãã«ãŒããŒãã¬ã¹ãçšããŠã400mgã®æé çšæ··åç©ãå§çž®ããããšã«ããäœæãããé溶
é Bã®çµæãè¡š5ã«ç€ºãã
å®æœäŸïŒã®é溶é Bããã³åžè²©ã®40mgãã¯ã¹ãã©(ç»é²åæš)é ã®in vitro 溶åºæåããïŒ%ã©ãŠãªã«ç¡«é žãããªãŠã 溶液1000mlãšUSPIIåè£ çœ®ãçšããŠæž¬å®ãããè¡šïŒã«ç€ºããããŒã¿ã¯ãé溶é Bã®ã»ãããã¯ã¹ãã©(ç»é²åæš)é ãããéã溶解ã瀺ããããšã瀺ããŠ
ããã
ããã€ãã®å¯Ÿç §ãã«ãã³ãã·ãé溶é (CïŒ-C5)ãã以äžã®äžè¬çæ¹æ³ã«åŸã£ãŠè£œé ããã
1ïŒãã«ãã³ãã·ããäºé žåçªçŽ ããã³äœæ圢æ§ã®ãã³ãããŒã«ãCo-mil äžã§ç²ç ããè¬å€ç²æ«æ··åç©ãäœæããã
2ïŒè¬å€ç²æ«æ··åç©ã¯æµåç¶æ ã§ããããã«ããŒã¹ãå«ã氎溶液ãæµåå±€ç²æ«ã«ã¹ãã¬ãŒ
ããŠé¡ç²ãåŸããã€ãã§æ¹¿ã£ãé¡ç²ãæµå局也ç¥ããã
3ïŒåŸããã也ç¥é¡ç²ããCo-mil ãçšããŠè£œç²å·¥çšã«ä»ãããã«ã§å å·¥ããé¡ç²ãåŸãã4ïŒãã«ã§å å·¥ããé¡ç²ã颚å³å€(ã¹ãã¢ãã³ãããããŒãã³ãããã§ãªãŒãã€ããŽïŒãŸãã¯ãªã¬ã³ãžé¢šå³ïŒãçå³å€(ã¢ã»ã¹ã«ãã¡ã K)ããã³æ»æ²¢å€(ã¹ãã¢ãªã³é žãã°ãã·ãŠã ããã³ã¹ãã¢ãªã³é ž)ãšæ··åããæ··åç©ãäœæããã
5ïŒã€ãã§ãã®æ··åç©400mgãå§çž®ããŠãçŽ1ãã2kbã®æåã®ç¡¬åºŠãæããé å€ãäœæããã
6ïŒæž©åºŠããã³çžå¯Ÿæ¹¿åºŠæ¡ä»¶ã®2çš®é¡ã®ç¹å®ã®ã»ããã®ç©ºæ°ã埪ç°ããŠãããã£ã³ããŒäžã§ããã®é å€ãåŠçãããæåã«ã25âã®æž©åºŠãš80%ã®çžå¯Ÿæ¹¿åºŠã®ç©ºæ°ããã£ã³ããŒäžçŽ60
å埪ç°ããããäºçªç®ã«ãçŽ40âã®æž©åºŠãš30%ã®çžå¯Ÿæ¹¿åºŠã®ç©ºæ°ããã£ã³ããŒäžçŽ60å埪
ç°ãããã
察ç
§ãã«ãã³ãã·ãé溶é C1-C5ã®çµæ(éé%)ãè¡š7ã«ç€ºãã
å®æœäŸ3ã®é溶é Bãå®æœäŸ5ã®å¯Ÿç §é溶é C1-C5ãæ¬çºæãšé¢é£ã®ç¡ããã«ãã³ãã·ãé溶é ãããã³ä»ã®æŽ»æ§æåãå«ãåžè²©ã®æº¶è§£é ãã以äžã®æ¹æ³ã«åŸã£ãŠå³èŠè©Šéšã§è©äŸ¡ããã4åãã5åã®å°éå®èœãããªã¹ããéžåºããåãããªã¹ã(ç·æ§/女æ§)ã®èã®äžã«é
溶é ãæäžããããããªã¹ãã¯ãåãŸãã«ãã®å£èã«å¯ŸããŠé å€ããã£ãã転ãããåæã«å®èœæ å ±ãšåŽ©å£å®äºæéãèšé²ãããå®èœæ å ±ã¯ã颚å³ã®è³ªãèŠå³ãè±ããããããå£åœãã(äŸãã°ãããããæ)ããã³ããšå³ãªã©ã®ãåé å€ã«é¢é£ããå®èœçç¹è³ªãå«ããé å€éã®ç¥èŠã«ããå·®ç°ãè¡šçŸããããã®åé¡å¥ã®åäœå°ºåºŠã«åŸã£ãŠããããã®ç¹è³ªã®ãããããèšèŒããã
é å€ãå
šãŠåŽ©å£ããåŸããããªã¹ãã¯ã30åéã«æž¡ã£ãŠå®èœçããšå³ãèšé²ãããåé å€ã«ã€ããŠ3åè©äŸ¡ããå
šãŠã®ãµã³ãã«ããããªã¹ãã«æ瀺ããããã«æå·åããã颚å³
ã®è³ªä¿æ°ããè©Šéšããããããã®çµæç©ã«äžããè¡š8ã«èšèŒãã(äœãã®ä¿æ°å€ã¯ïŒããè¯ãå šè¬çãªé¢šå³ã®è³ªã瀺ãïŒãåçµæç©ã®ããããŸãè©äŸ¡ããããããæä¿æ°å€ãšããŠè¡š8ã«èšé²ãã(ä¿æ°å€ãäœãã»ã©ãããããæãå°ãªããæ»ãããªçµæç©ã§ããïŒãããã«ãé å€åŽ©å£æéãè©äŸ¡ããŠè¡šïŒã«èšé²ããã
ã®è³ªä¿æ°ããè©Šéšããããããã®çµæç©ã«äžããè¡š8ã«èšèŒãã(äœãã®ä¿æ°å€ã¯ïŒããè¯ãå šè¬çãªé¢šå³ã®è³ªã瀺ãïŒãåçµæç©ã®ããããŸãè©äŸ¡ããããããæä¿æ°å€ãšããŠè¡š8ã«èšé²ãã(ä¿æ°å€ãäœãã»ã©ãããããæãå°ãªããæ»ãããªçµæç©ã§ããïŒãããã«ãé å€åŽ©å£æéãè©äŸ¡ããŠè¡šïŒã«èšé²ããã
ãããè¯å¥œãªå šè¬ç颚å³ã®è³ªïŒããäœã颚å³ã®è³ªä¿æ°ïŒã瀺ãããããã«ãé溶é Bã¯ã
å¯Ÿç §ãã«ãã³ãã·ãé溶çµæç©C1-C5ã®ã©ããããããã匱ãããããæã®å£åœãã(ããäœãããããæä¿æ°å€)ã瀺ãããæåŸã«ãé溶é Bã¯ãå¯Ÿç §ãã«ãã³ãã·ãé溶çµæç©C1-C5ã®ã©ãããããéã厩å£æéã瀺ããã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35017901P | 2001-11-07 | 2001-11-07 | |
PCT/US2002/035664 WO2003039472A2 (en) | 2001-11-07 | 2002-11-07 | Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005512990A JP2005512990A (ja) | 2005-05-12 |
JP2005512990A5 true JP2005512990A5 (ja) | 2005-12-22 |
Family
ID=23375540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003541764A Pending JP2005512990A (ja) | 2001-11-07 | 2002-11-07 | æµåå±€é ç²æ³ã«ãã補é ãããå£è å 厩å£åãã«ãã³ãã·ãçµæç© |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1446088A2 (ja) |
JP (1) | JP2005512990A (ja) |
AU (1) | AU2002361596A1 (ja) |
BR (1) | BR0213973A (ja) |
CA (1) | CA2466030A1 (ja) |
MX (1) | MXPA04004290A (ja) |
WO (1) | WO2003039472A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8183287B2 (en) * | 2006-06-12 | 2012-05-22 | Schering Corporation | Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders |
CN101762646B (zh) * | 2008-12-26 | 2012-09-05 | æ¬åæ±è¯äžéå¢æéå ¬åž | äžç§æµå®æå æ¿éå«éçæ¹æ³ |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
EP0745382B1 (en) * | 1994-01-31 | 2003-11-12 | Yamanouchi Pharmaceutical Co. Ltd. | Intraorally soluble compressed molding and process for producing the same |
JPH0867623A (ja) * | 1994-08-31 | 1996-03-12 | Taisho Pharmaceut Co Ltd | ç¯å³çµå£è£œå€çšçµæç© |
DE19617487A1 (de) * | 1996-05-02 | 1997-11-06 | Merck Patent Gmbh | Geschmacksverbesserung von Arzneimittelwirkstoffen |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | ج٠د٠سÙر٠اÙد ÙÙ | ٠رÙؚات سÙÙÙÙÙÙسÙØš celecoxib |
ATE283048T1 (de) * | 1999-12-08 | 2004-12-15 | Pharmacia Corp | Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt |
JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ãã¡ã«ãã·ã¢ ã³ãŒãã¬ã€ã·ã§ã³ | ãŽã¡ã«ãã³ãã·ãçµæç© |
CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | æ³ç西é åæ®çºŠç¿°çŸåœå ¬åž | æ²»çæçŸæ§éç¢çååç© |
-
2002
- 2002-11-07 CA CA002466030A patent/CA2466030A1/en not_active Abandoned
- 2002-11-07 AU AU2002361596A patent/AU2002361596A1/en not_active Abandoned
- 2002-11-07 WO PCT/US2002/035664 patent/WO2003039472A2/en not_active Application Discontinuation
- 2002-11-07 BR BR0213973-1A patent/BR0213973A/pt not_active IP Right Cessation
- 2002-11-07 JP JP2003541764A patent/JP2005512990A/ja active Pending
- 2002-11-07 EP EP02797073A patent/EP1446088A2/en not_active Withdrawn
- 2002-11-07 MX MXPA04004290A patent/MXPA04004290A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2292614T3 (es) | Formulacion oral de fusion rapida de un inhibidor de ciclooxigenasa-2. | |
JP2005506987A (ja) | æèŠçã«èš±å®¹ãããå£å 厩å£æ§çµæç© | |
JP2004506680A (ja) | ã·ã¯ããªãã·ã²ããŒãŒâïŒé»å®³å€ã®è¿ é厩å£çµå£è£œå€ | |
HRP20010582A2 (en) | Valdecoxib compositions | |
US20020119193A1 (en) | Oral fast-melt formulation of a cyclooxygenase-2 inhibitor | |
AU2001286530A1 (en) | Oral fast-melt formulation of a cyclooxygenase-2 inhibitor | |
JP2005512990A5 (ja) | ||
JP2005512990A (ja) | æµåå±€é ç²æ³ã«ãã補é ãããå£è å 厩å£åãã«ãã³ãã·ãçµæç© | |
JP2005508348A (ja) | åŽé§ä¹Ÿç¥æ³ã«ãã補é ãããå£å ã§åŽ©å£ãããã«ãã³ãã·ãçµæç© | |
AU2002341796A1 (en) | Intraorally disintegrating valdecoxib compositions | |
AU2002347852A1 (en) | Intraorally distintegrating valdecoxib compositions prepared by spray drying process |